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Chapter 1 
Introduction 
1.1 General introduction 
Extensive studies have been performed on the development of anticancer drugs. Many dif-
ferent compounds have been shown to exhibit anticancer activity through different mecha-
nisms. Anticancer drugs often exhibit their activity by using specific biochemical properties 
of the tumor cells. In general, tumor cells have an accelerated metabolism as compared to 
their normal counterparts in accordance with their higher cell growth and proliferation rate 
(1-7). Most anabolic routes are enhanced in tumor cells, whereas catabolic routes are less 
active (8-11). This imbalance increases with the malignant state of the tumor cells (2,3,8, 
10,11) and can be used as a tool for cancer therapy. Drugs, which resemble natural occur-
ring cellular metabolites, can be used to deregulate tumor cell metabolism in order to induce 
cytotoxicity. These drugs are called antimetabolite. Several metabolic pathways can be used 
as targets for therapy with antimetabolite. One of these routes is the purine nucleotide 
synthesis, in which for instance 6-mercaptopurine (6MP) exerts its anticancer activity. 
1.2 Purine metabolism 
Purine nucleotides are biosynthesized by the purine de novo synthesis (PDNS, Scheme 1) 
and are required for RNA and DNA synthesis (12). In a process involving eleven reactions 
the purine ring is built, starting from ribose 5'-phosphate (R-5-P) and ending with the 
formation of IMP. IMP is converted into AMP or GMP by the purine interconversion path-
ways. A total of seven high-energy phosphate molecules is required for the ultimate 
formation of one molecule AMP. Eight high-energy phosphates are necessary for the for-
mation of GMP. So, biosynthesis of purine nucleotides is an energy consuming pathway. 
Nucleosidemonophosphate kinases and nucleosidediphosphate kinases catalyze the phosphor-
ylation of GMP and AMP into GTP and ATP, respectively. These reactions require ATP 
(12,13). The activity of the PDNS is regulated by feedback-inhibition by the purine 
nucleotides. These nucleotides inhibit the second enzyme in the PDNS, phosphoribosyl 
pyrophosphate amidotransferase, which catalyses the conversion of PRPP into phosphoribos-
ylamine (PRA) (14). The purine interconversion pathway is also regulated by feedback-
inhibition, since GMP inhibits IMP dehydrogenase, and AMP inhibits adenylosuccinate 
synthetase. Furthermore, reciprocal regulation of GMP and AMP synthesis occurs, since 
ATP is a co-factor for the synthesis of GMP, and GTP for AMP synthesis (12). 
Apart from being involved in RNA and DNA synthesis, purine nucleotides are used for 
many purposes. ATP functions as energy donor for numerous cellular processes (13). GTP 
can also function as energy donor. Moreover, guanine nucleotides play an important role in 
12 
Chapter 1 
Scheme 1. Purine metabolism 
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(1) hypoxamhine-guanine phosphoribosyltransferase (HGPRT); (2) adenine phosphoribosyltransferase(APRT); 
(3) inosinic monophosphate dehydrogenase (1MPDH); (4) guanosine monophosphate synthetase (GMPS); (5) 
adenylosuccinate synthetase; (6) adenylosuccinate lyase; 
(7) purine 5'-nucleotidase (5'NT); (8) purine nucleoside Phosphorylase (PNP); (9),(10),(11) xanthine oxidase; 
(12) adenosine kinase (AK); (13) phosphoribosyl pyrophosphate (PRPP) synthetase (PRPPS); 
(14) phosphoribosyl pyrophosphate amidolrans/erase. 
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various anabolic processes, such as protein synthesis, intracellular cell signaling, polyamine 
synthesis and microtubule assembly (15-17). 
Products of purine nucleotide catabolismi are adenosine, guanine and hypoxanthine. 
Adenosine is converted into inosine and then into hypoxanthine. Guanine is degraded into 
xanthine. Hypoxanthine and xanthine are degraded further by xanthine oxidase into uric 
acid, which is the end product of purine catabolism in man. This degradation of purine 
bases can be prevented by the purine salvage pathway (Scheme 1). In this way, the loss of 
the purine ring, which is energetically expensive to build, can be prevented (12,18). 
Hypoxanthine and guanine are converted into IMP and GMP, respectively, by hypoxan-
thine-guanine phosphoribosyltransferase. Cleavage of 5'-deoxy-5'-methylthio-adenosine (the 
nucleoside end product of polyamine synthesis) into S'-methylthioriboside-l-phosphate 
results in formation of adenine, which is salvaged into AMP by adenine phosphoribo-
syltransferase. All these reactions use PRPP as a co-substrate. 
In most cells the main route of purine formation is the purine salvage pathway (3,19). In 
malignant lymphoblasts purine salvage and especially purine de novo synthesis exhibit a 
higher activity as compared to peripheral blood lymphocytes (2,4,8-11,19-21). 
1.3 Mechanisms of 6-mercaptopurine cytotoxicity 
6MP is an analogue of the natural purine base hypoxanthine and is metabolized by a simi-
lar metabolic route. It was first synthesized in 1952, by Elion and Hitchings (22). Soon 
thereafter, its antileukemic activity was reported by Burchenal et al. (23). 6MP in combina-
tion with methotrexate (MTX) is the cornerstone of the maintenance treatment of children 
with acute lymphoblastic leukemia (ALL) (24). Combination of these two drugs improves 
therapy results as compared to either drug alone, as demonstrated in earlier clinical trials 
(25) and biochemically in vitro in our laboratory (26,27). During maintenance treatment 
both 6MP and MTX are administered orally in a low dose. In most regiments 6MP is given 
daily, whereas MTX is administered once a week (24). However, after the introduction of 
intravenous administration of MTX and the biochemical evidence for a potential synergism 
between 6MP and MTX (26,27), both drugs have also been used intravenously with good 
clinical results (28). At this moment an extensive pharmacokinetic and pharmacological 
study is undertaken in the Dutch Childhood Leukemia Study Group protocol ALL-8, using 
intravenous MTX and 6MP during consolidation therapy. 
The difference between 6MP and its analog hypoxanthine is the presence of a mercapto-
(SH) group, instead of a hydroxy-(OH) group (Fig. 1) at the 6th position of the purine ring. 
14 
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Scheme 2. Metabolism of 6-mercaptopurine 
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The numbers of the enzymes correspond to the numbers at scheme 1; (15) thiopurine methyltransfe-
rase (TPMT) 
6MP enters the cells by facilitated transport by the hypoxanthine carrier (29). 6MP is not 
cytotoxic by itself, but has to be converted in order to exert cytotoxic activity. The first step 
is conversion into thioIMP (tIMP) by the purine salvage enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) (30,31) (Scheme 2). tIMP can be further metabolized 
by two pathways. 
First, AMP can be converted by the purine interconversion into thio-GMP (tGMP) (Scheme 
2). The enzymes catalyzing this metabolic conversion are IMP dehydrogenase (IMPDH) and 
GMP synthetase (GMPS). IMPDH is the rate-limiting enzyme in this route (1) and as 
mentioned above, this enzyme is subject to end product inhibition by GMP. tGMP is 
converted further by GMP and GDP kinase and ribonucleotide reductase, to form tGTP and 
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Fig. 1. Structural formula of hypoxanthine and its analogue 6-mercaptopurine. 
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deoxytGTP, which are incorporated into RNA and DNA of the cells, respectively (27,32-
44). Incorporation into DNA is the most important one of these routes (27,33,36,37), 
inducing DNA damage, such as single strand breaks (38-40,43,44), DNA-protein cross-links 
(41,43), interstrand cross-links (43) and sister chromatid exchanges (42,43). This results in 
delayed cytotoxicity in most tumor cell lines and is commonly thought to be the main cause 
for 6MP cytotoxicity (37,39,44-48). This process of delayed cytotoxicity is reflected by 
growth arrest of the tumor cells in the G2 + M phase of the cell cycle (36,46). 
The second route of tIMP metabolism is methylation by thiopurine methyltransferase into 
methyl-thioIMP (Me-tIMP, Scheme 2) (49). The predominant route of Me-tIMP formation 
appears to be via methylation of ÜMP (50). This conversion is S-adenosylmethionine 
(AdoMet) dependent (50-54). Me-tIMP is a very strong inhibitor of the PDNS (14,55-57). 
Inhibition occurs at the second enzyme in this route, PRPP amidotransferase, catalyzing 
conversion of PRPP into PRA (14,50,52,58-62). Next to Me-tIMP tIMP also inhibits 
PDNS, but Me-tIMP is the most effective of the two (50). Inhibition of PDNS can provoke 
cytotoxicity by several different mechanisms: 
1. Inhibition of PRPP amidotransferase results in accumulation of PRPP (36,45,63,64). 
Since PRPP is a co-substrate for the intracellular incorporation and conversion of 6MP, an 
increase in PRPP concentration induces an increase in the incorporation of 6MP into the 
cells and autostimulation of 6MP cytotoxicity occurs (36,52,65-67). 
2. Inhibition of the PDNS by Me-tIMP results in a depletion of endogenous purine nucleo-
tides (36,58,61,62,68). Purine nucleotides are involved in many metabolic processes, as 
described earlier. Tumor cells have a high need of purine metabolites for cell growth and 
proliferation. Depletion of these purine nucleotides results in inhibition of RNA and DNA 
synthesis (36) and may inhibit many other purine nucleotide dependent processes in the 
cells. This results in growth inhibition of the tumor cells in late G, + S phase of the cell 
cycle and induces inhibition of cell growth and, after high dose or prolonged administra-tion 
16 
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of 6MP, cytotoxicity (36,62,69). 
3. The excess of PRPP, which results from inhibition of PDNS at PRPP amidotransferase, 
induces an increase of pyrimidine biosynthesis, since the PRPP concentration regulates this 
pathway (47,61,62,68,70-72). Taken together with the decrease of the purine concentrati-
ons, the increase of pyrimidine nucleotides may lead to unbalanced growth, which can also 
result in cell growth inhibition. 
Besides these mechanisms of 6MP cytotoxicity, metabolites of 6MP are known to interfere 
with several other enzymes of purine metabolism. For instance, high concentrations of tIMP 
inhibit IMPDH, the rate-limiting enzyme of the purine interconversion pathway involved in 
guanine nucleotide biosynthesis (52,60,73-76). tIMP also inhibits GMPS, the other purine 
interconversion enzyme involved in guanine nucleotide biosynthesis (75). At high concentra-
tions, tIMP may inhibit both adenylosuccinate synthetase and adenylosuccinate lyase, the 
enzymes catalyzing the conversion of IMP into AMP (52,60,75-77). Furthermore, as menti-
oned before, ÜMP inhibits PDNS, although not as potent as Me-tIMP. tGMP inhibits 
IMPDH, as well as GMP kinase, PRPP amidotransferase and HGPRT (47). 
The importance of the methylation route for 6MP cytotoxicity has yet not fully been under-
stood. The metabolism of Me-tIMP can be studied more specifically by using methylmerca-
ptopurine ribonucleoside (Me-MPR), another thiopurine antimetabolite of which Me-tIMP is 
a metabolite. Transfer of cells which are treated with Me-MPR into drug-free and purine 
rich medium results in reversal of the growth-inhibitory activity of Me-MPR and a decrease 
of the concentration of Me-tIMP in the cells (61). The reversal of growth inhibition can be 
ascribed to repletion of purine nucleotides as a result of salvage of the freshly added purine 
nucleotide precursors, present in the drug-free medium. But it may also be caused by the 
decrease of intracellular Me-tIMP concentrations, observed after the transfer of the cells 
into the drug-free medium. This decrease may indicate conversion of Me-tIMP into 
methylmercaptopurine ribonucleoside (Me-MPR), followed by extracellular excretion (61). 
However, other studies indicated that Me-tIMP concentrations diminished only slowly 
(78,79). Demethylation of Me-tIMP is reported to occur in vivo in the rat. Until now the 
enzyme catalyzing this reaction has been found exclusively in the liver (65), so this 
catabolic pathway for Me-tIMP seems to be of no importance in leukemia cells. Further-
more, it is generally assumed that phosphorylation of Me-tIMP does not occur (56,80,81). 
However, two reports have mentioned formation of Me-tIDP and Me-tITP in human 
peripheral blood leukocytes and nucleated marrow cells in vitro and in patients receiving 
6MP treatment (82,83), so this statement remains to be elucidated. Our previous studies did 
not give any indication of the formation of these metabolites. Overall, the metabolic fate of 
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Me-tIMP is not yet fully elucidated. 
A distinction between inhibition of PDNS and cytotoxicity of 6MP was made by Tidd et al. 
(45). They concluded that inhibition of PDNS was not centrally involved in the delayed cy-
totoxic activity of 6MP, but that 6MP cytotoxicity rather depended on incorporation of 
thioguanine nucleotides into DNA. This conclusion was based on the observation that 
exposure of L5178Y mouse lymphoma cells to Me-MPR resulted in depletion of purine nuc-
leotide concentrations and cell proliferation, but that it did not affect cell viability. After 
Me-MPR was removed, cell proliferation returned to control values. In contrast, a brief ex-
posure of these cells to 6MP had a slight effect on the cellular purine nucleotide concen-
trations, but it did induce a delayed cytotoxic reaction, as a result of the incorporation of 
thioguanine nucleotides into the DNA. 
Similar conflicting ideas also exist with respect to the clinical relevance of the methylation 
route of 6MP. Wide interindividual differences exist in the activity of TPMT, as a result of 
a common genetic polymorphism (53). Overall, 1 in 300 normal subjects exhibits undetect-
able TPMT activity, 11 percent of the population has intermediate activity and the remain-
der of the population high activity (53). A reciprocal correlation between TPMT activity 
and formation of thioguanine nucleotides exists (84-86). In patients who received oral 6MP 
treatment and who developed a severe leukocytopenia as a result of the treatment, low 
TPMT activities were measured. These low actvities led to high concentrations of thiogua-
nine nucleotides in red blood cells, correlated with toxicity (86,87). Furthermore, children 
with ALL who exhibited a high TPMT activity in red blood cells had a poorer prognosis as 
compared with patients with an intermediate TPMT activity in red blood cells after 6MP 
treatment (88). In this view, methylation is considered to be a detoxification pathway for 
6MP. 
On the other hand, however, it was reported that the concentration of 6MP required to in-
duce a 50 % inhibition of DNA synthesis in phytohemagglutinin stimulated peripheral blood 
lymphocytes was higher in subjects with a genetically low TPMT activity compared to sub-
jects with genetically normal or high TPMT activity. This seems to indicate that methylated 
metabolites of 6MP are important for cytotoxicity (85). So, the clinical relevance of the 
methylation route for 6MP cytotoxicity is far from clear and is one of the subjects of the 
ALL-8 study of the Dutch Childhood Leukemia Study Group, using intravenous 6MP in 
children with ALL. 
1.4 Mechanisms of methylmercaptopurine ribonucleoside cytotoxicity 
Methylmercaptopurine ribonucleoside (Me-MPR) is another purine antimetabolite. This cy-
tostatic drug is an analogue of the purine nucleoside adenosine (Fig. 2). Me-MPR induces 
inhibition of cell growth and cell death in tumor cells in vitro (61,62,80,89). Furthermore, 
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Fig. 2. Structural formula of adenosine and its analogue methylmercaptopurine ribonucleoside. 
N H , 
I 
N С 
I II 
N 
II 
C H 
S C H , 
I 
H 4 /C\/C H 
N
 Ν N 
о^н.сон о^н.сон 
C H C H 
\ H 
i,-
H/ 
1. 
\H 
5r 
H / 
•5. 
elhylmercaptopunne 
ribonucleoside 
Me-MPR is effective in experimental tumors resistant to 6MP (80), which is probably the 
result of the fact that the development of cellular resistance to 6MP is commonly associated 
with the loss of HGPRT activity. HGPRT converts 6MP into its cytotoxic form, tIMP (90), 
whereas Me-MPR is conversed by adenosine kinase (AK) into Me-tIMP (56,65,80,91-93) 
(Scheme 3). As discussed above, Me-tIMP inhibits PDNS, leading to inhibition of cell 
growth and cytotoxicity. Synergism is observed between 6MP and Me-MPR (63,64). This 
synergism is based on the same mechanism as the autostimulation of 6MP cytotoxicity des­
cribed earlier. It can be ascribed to an increase of the PRPP concentration as a result of the 
inhibition of PDNS by Me-tIMP. As a result more 6MP can be incorporated into the cells 
by HGPRT, since PRPP is the co-substrate for this conversion, and an increase in cytotox­
icity results. 
1.5 Aim of the present study 
In our laboratory extensive studies have been performed to elucidate the mechanisms of 
cytotoxicity of 6MP (94,95). From these studies a possible role for formation of Me-tIMP 
for 6MP cytotoxicity emerged. This was in contrast with the studies of others, who regar­
ded Me-tIMP formation as detoxification pathway (85-88). 
In this study special attention is paid to the importance of the methylation route for 6MP 
cytotoxicity. The effects of high dose versus low dose 6MP are evaluated in a human 
malignant T-lymphoblasüc cell line, Molt F4. It is especially important to gain more insight 
in the mechanisms of cytotoxicity of high dose 6MP, because at this moment clinical trials 
with intravenously administered 6MP are performed. As a result, much higher plasma 
concentrations of 6MP are reached as compared with oral administration. 
Molt F4 cells have a highly active purine salvage and PDNS (26), so 6MP can be easily 
incorporated and can fully exert its effects on DNA, RNA and PDNS. 
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Scheme 3. Metabolism of methylmercaptopurine ribonucleoside 
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The numbers of the enzymes correspond to those of schemes 1 and 2. 
To obtain a better insight in the contribution of Me-tIMP to 6MP cytotoxicity, conversion 
of tIMP into tGMP was prevented in some studies by inhibition of IMPDH. In that way the 
effects of 6MP via the methylation route could be studied specifically. Inhibition of IMPDH 
was obtained by mycophenolic acid (MPA), a well known and specific inhibitor of IMPDH 
(96,97). 
In chapter 2 the development of a sensitive micro-assay for the measurement of IMPDH 
activity and the effects of MPA on IMPDH activity are described. 
In chapter 3 the effects of inhibition of IMPDH on cell growth and cell viability are 
described. Endogenous nucleotide concentrations have been determined, to obtain insight in 
the MPA-effects on purine and pyrimidine metabolism. 
Chapter 4 deals with the importance of Me-tIMP formation for cytotoxicity of 6MP after 
administration of 6MP alone, or in combination with MPA. The effects of addition of both 
drugs are monitored by determination of cell growth and cell viability and by determination 
of endogenous nucleotides and metabolites of 6MP. 
In chapter 5 the effects of Me-tIMP formation on cellular cytotoxicity are studied in more 
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detail by the use of Me-MPR, since Me-tIMP is the sole metabolite of Me-MPR. In this 
chapter the effects of several concentrations of Me-tIMP on cytotoxicity and inhibition of 
PDNS are established, the latter being determined by measuring both the increase of PRPP 
concentration and the decrease of endogenous purine nucleotides. 
The importance of Me-tIMP formation and subsequent inhibition of PDNS were further eva­
luated in the chapters 6 and 7. In chapter 6 experiments are described in which 6MP is 
combined with amidoimidazolecarboxamide ribonucleoside (AICAR). AICAR is an inter­
mediate of the purine de novo synthesis, distal to the PDNS inhibition site of Me-tIMP. 
Therefore, AICAR is able to circumvent this inhibition. Since Me-MPR is also converted 
into Me-tIMP, the effects of the combination of Me-MPR and AICAR are also described. 
Chapter 7 deals with prevention of Me-MPR cytotoxicity by intermediates of the purine 
salvage pathway adenosine, adenine, inosine and guanosine, and evaluates the importance of 
the different nucleotide pools for Me-tIMP cytotoxicity. 
Finally, a new mechanism by which the methylation pathway of 6MP can influence cell 
proliferation is proposed in chapter 8. As a result of 6MP treatment and methylation of 
tIMP a decrease in the S-adenosyl homocysteine (AdoMet) concentration occurs. Since 
AdoMet is a universal methyl-donor involved in methylation of many different intracellular 
molecules, for instance proteins, lipids and nucleic acid, a decrease of its concentration may 
disrupt cellular processes, leading to inhibition of cell growth and cytotoxicity. 
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Chapter 2 
6-Mercaptopurine metabolism in two leukemic cell lines 
Introduction 
6-Mercaptopurine (6MP), an analogue of the purine base hypoxanthine, is commonly used 
in the maintenance therapy of acute lymphoblastic leukemia (ALL) in children (1). 
The first step of 6MP cytotoxicity is intracellular conversion into thio-IMP (tIMP) by the 
enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT). tIMP can be further 
metabolized by two pathways. Firstly, it can be converted into thioguanine nucleotides by 
the purine interconversion route (2,3). Subsequently, these thioguanine nucleotides are 
incorporated into RNA, and in particulary into DNA (4,5). Incorporation of thioguanine 
nucl-eotides into DNA results in delayed cytotoxicity, probably due to induction of DNA 
damage (6,7). The rate limiting enzyme in this metabolic route is IMP dehydrogenase 
(IMPDH) (8), and as such its activity is of importance for the efficacy of 6MP cytotoxi-
city. Secondly, tIMP can be methylated by thiopurine methyltransferase (TPMT) (9,10). 
Methyl-thioIMP (Me-tIMP) formed by this reaction is a strong inhibitor of the purine de 
novo synthesis (PDNS) (11) and this may also contribute to the cytotoxicity of 6MP by 
induction of depletion of normal nucleotides for DNA and RNA synthesis. 
One of the possibilities to elucidate the role of both metabolic routes in the effectiveness of 
6MP therapy is to inhibit either one of them. In this study mycophenolic acid (MPA), a 
specific inhibitor of IMPDH was used to inhibit the conversion of 6MP into thioguanine 
nucleotides. A microassay for IMPDH was developed, based on the assay des-cribed by 
Uchida et al (2). IMPDH activity was determined in two leukemic cell lines, Molt F4 (a T-
ALL cell line) and KM, (a non-T-non-B cell line). The effects of MPA on cell growth, cell 
viability, IMPDH activity and cellular nucleotide concentration were determined. 
Materials and methods 
6MP was purchased from Wellcome bv, Netherlands, MPA from Sigma Chemicals, USA, 
and 14C-IMP from Amersham international, UK. 
Cell culture 
The experiments were performed with Molt F4, a T-ALL cell line, and with KM3, a non-T-
non-B cell line. The cells were cultured in RPMI 1640 DM (Gibco, Netherlands), supple-
mented with 10 % non-dialyzed fetal calf serum (Gibco, Netherlands), 2 mM L-glutamine 
(Sigma Chemicals, USA), 2 mM sodium pyruvate (BDH Chemicals Ltd, UK) and gentami-
cin/streptomycin, thrice a week. The cell cultures were maintained in a S % C02 humified 
atmosphere at 37°C. The absence of mycoplasma contamination and the presence of marker 
antigens were tested regularly. 
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IMPDH assay 
For determination of the IMPDH activity a microassay was developed, based on the assay 
described by Uchida et al (2). Cells were lyophilized overnight and were incubated with 
1.61 мтоі Tris/HCl (Sigma Chemicals, USA) pH 8.0, 12.9 nmol reduced glutathione 
(GSH, sigma Chemicals, USA), 3.23 nmol EDTA (Siegfried AG, BDR), 3.23 nmol NAD+ 
(Sigma Chemicals, USA), 0.16 /¿mol KCl (Merck, BDR) and 2.9 nmol [8-l4C]IMP, for 60 
minutes at 37°C. The reaction volume was 10 μΐ. Substrate and product formed were sepa­
rated by means of thin layer chromatography. The radioactivity was counted in a liquid 
scintillation counter (Delta, Netherlands). The specific activity (SA) of the enzyme was 
expressed as nmoles product. 10* viable cells, h"1. 
The effect of inhibition of IMPDH activity by MPA was studied in cell lysates. 
Determination of endogenous nucleotides 
After cell culture during 4 hours in the presence of various concentrations of MPA the cells 
were harvested, counted in a coulter counter and cell viability was determined. Nucleotides 
were extracted from 3 χ 10* viable cells and stored at -20°C until analysis. Nucleotide 
concentrations were determined by means of HPLC (12). 
Cell growth and viability assays 
Cell growth and viability experiments were performed in logarithmically growing cells, 
which were seeded 24 hours prior to the start of the experiment. At this time 6MP, MPA or 
a combination of both were added as a single dose. During the experiment 2 mM glutamine 
was supplemented every 24 hour, in order to prevent glutamine exhaustion of the medium. 
Cells were harvested and counted in a coulter counter. Cell viability was determined by the 
trypan blue exclusion. 
Results 
The specific activity of IMPDH was higher in Molt F4 cells as compared to KM3 cells (1.9 
± 0.2 nmoles product. IO"6 viable cells.h1 (mean ± SEM), η = 60 versus 1.1 ± 0.1, η = 
11). MPA appeared to be a strong inhibitor of IMPDH (Fig. 1). The inhibition was 
concentration de-pendent. A fifty percent inhibition of the enzyme activity was observed in 
the presence of 0.2 μΜ MPA. With 5 μΜ MPA virtually no IMPDH activity could be 
detected. 
The inhibition of IMPDH by MPA was reflected by a decrease of intracellular guanine nuc­
leotide levels (Fig. 2). When cells were incubated during 4 hours with 0.8 μΜ MPA, a fifty 
percent reduction of the guanine nucleotide level was observed. 
Both 6MP and MPA were cytotoxic for Molt F4 cells (Fig. 3a, 3b). The effects of the 
drugs were more pronounced on cell growth (fig. 3a) than on cell viability. The 
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Fig. 1. Inhibition of IMPDH activity (mean ± SD, n=15)from Molt F4 cells by MPA. The IMPDH 
activity was determined in tysates of 25,000 Molt F4 cells in the presence of various concentrations 
ofMPA. 
Guanine (% of control) 
Fig. 2. Effect of MPA on the cellular guanine nucleotide concentration of Molt F4 cells. The cells 
were incubated in various concentrations of MPA for 4 hours (mean ± SD, n=3). 
remaining viability after an incubation with 2 μΜ 6MP during 48 hours was 80 % of con­
trol. Cell growth, however, was decreased to 45 % of control. The combination of 6MP 
and MPA resulted in a synergistic decrease of cell growth and cell viability (Fig. 3a,b). 
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Fig. 3. Effects of 2 μΜ 6MP, 0.5 μΜ ΜΡΑ and the combination of both drugs on cell viability (a) 
and cell growth φ) of Molt F4 cells. Viability and cell growth were expressed as percentage of 
untreated cells (mean ± SD, η=5). 
Discussion 
The results of this study show that IMPDH activity is higher in Molt F4 cells than in KM3 
cells. Earlier studies in our laboratory demonstrated that Molt F4 cells also exhibit a more 
active PDNS and purine salvage pathway activity (13). These observations indicate that the 
purine flow to guanine nucleotides is higher in Molt F4 cells than in KM3 cells. 
MPA inhibits IMPDH in a concentration dependent manner (Fig. 1). The inhibition of 
IMPDH is reflected by a decrease of intracellular guanine nucleotide levels (Fig. 2). The 
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guanine nucleotide concentration decreases to 40 % of control values when cells are 
incubated during 4 hours with 5 μΜ MPA. These results are in accordance with data from 
earlier studies (14). The inhibition of IMPDH, however, in the presence of 5 μΜ MPA, is 
much more pronounced than indicated by the guanine nucleotide concentration; hardly any 
IMPDH activity is present (Fig. 1). The presence of measurable guanine nucleotide levels 
after 4 hours may reflect the production of guanine nucleotides by the salvage pathway. 
MPA is cytotoxic for Molt F4 cells. Cytotoxicity may be the result of induction of deple­
tion of guanine nucleotides. Firstly, depletion of guanine nucleotides may inhibit DNA and 
RNA synthesis. Secondly, this depletion could hamper intracellular signal transduction, as 
guanine nucleotide binding proteins (G-proteins) are often involved in this process (15,16). 
Alternatively, the observed cytotoxicity can be the result of increased IMP, which is an 
inhibitor of PDNS (11). Inhibition of purine synthesis may lead to decreased DNA and 
RNA synthesis, resulting in inhibition of cell growth and cell viability, in particulary 
because Molt F4 cells depend on a high PDNS activity (13). 
6MP cytotoxicity can be caused by incorporation of thioguanine nucleotides into DNA and 
RNA and by formation of Me-tIMP, an inhibitor of PDNS. This study shows that methyla-
tion of tIMP is an important route for 6MP cytotoxicity. This can be concluded from the 
observed synergistic effect of the combination of 6MP and MPA on the cell viability. MPA 
inhibits IMPDH and thereby the conversion of 6MP into guanine nucleotides. The methyla-
tion of tIMP into Me-tIMP by TPMT remains the only route available. Also, a substantial 
quantity of Me-tIMP could be delected when cells were grown in the presence of 6MP 
(results not shown). Me-tIMP is a strong inhibitor of the PDNS (11). As the PDNS is 
inhibited, the intracellular PRPP concentration rises (13). PRPP is a co-substrate needed for 
the conversion of 6MP into tIMP. So, as a result of the increase of the PRPP concentration 
more 6MP can be converted into tIMP. In this way, a auto-enhancement of 6MP incorpora­
tion may occur. 
Since 6MP and MPA demonstrated a severe inhibition of cell growth when added separate­
ly, no conclusion can be drawn about a synergistic effect of the combination of both drugs 
on cell growth. 
In these experiments the effects of 6MP and MPA on cell growth can be observed at an ear­
lier stage and are more pronounced than the effects on cell viability. First cell growth 
inhibition is induced by the inhibition of intracellular metabolic activity caused by 6MP and 
MPA. Then, as a result of this, cell death occurs. So, biochemical changes occur before 
cell death can be detected. 
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Inhibition of IMP dehydrogenase by mycophenolic acid in Molt F4 human 
malignant lymphoblasts 
Summary 
The effects of inhibition of IMP dehydrogenase (IMPDH), the rate-limiting enzyme in gua­
nine nucleotide de novo synthesis, on cell growth, cell viability, endogenous nucleotide 
concentrations and concentrations of extracellular nucleosides and bases were studied in 
Molt F4 human malignant lymphoblasts. Mycophenolic acid (MPA) was used as a specific 
inhibitor of the enzyme activity. IMPDH activity was maximally inhibited with 0.5 /iM 
MPA. After a 2 h exposure of the cells to 0.5 μΜ MPA, guanine nucleotides were deple­
ted to approximately 50 % of control values, whereas 5-phosphoribosyl-l-pyrophosphate 
(PRPP) levels increased to approximately 200 %. Under these conditions, cytotoxicity 
became obvious after 24 h. Depletion of guanine nucleotides and cytotoxicity were pre­
vented by addition of guanosine to MPA treatment. Daily supplements of guanosine were 
required to prevent MPA cytotoxicity during the entire incubation period of 72 h. We 
conclude that depletion of guanine nucleotides, induced by treatment with MPA, induces a 
severe and rapid cytotoxicity in Molt F4 cells. 
Introduction 
IMP dehydrogenase (IMPDH) is a key enzyme in purine interconversion. It catalyses the 
conversion of IMP into XMP and is the rate-limiting enzyme in the de novo synthesis of 
guanine nucleotides (1). Guanine nucleotides play an important role in various anabolic 
cellular processes, such as protein synthesis, intracellular cell signalling, polyamine 
synthesis and microtubule assembly. Furthermore, guanine nucleotides are necessary for 
RNA and DNA synthesis and for several specific enzyme reactions and function as energy 
donors for numerous metabolic processes in cells (2-5). 
Tumor cells exhibit a high need for nucleotides, as their metabolism is accelerated to 
facilitate cell proliferation. Therefore, activities of many enzymes controlling purine and 
pyrimidine metabolism show marked differences in lymphoblasts as compared with lympho­
cytes (1,6,7). IMPDH is also reported to have a higher activity in tumor cells as compared 
to normal cells (1,8,9). Two isoenzymes of IMPDH are known, type I and type II, of 
which type II-mRNA and enzyme activity are upregulated in tumor cells (10,11). 
Inhibition of de novo synthesis of guanine nucleotides and subsequent depletion of the 
guanine nucleotide pool may induce cytotoxicity, especially in tumor cells with their high 
IMPDH activity. Several inhibitors of IMPDH are known to exhibit an antitumor activity 
(12-15). One of these inhibitors is mycophenolic acid (MPA), a toxic metabolite produced 
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by pénicillium species (16). MPA is a specific inhibitor of IMPDH (12,17)· It binds to the 
NAD+ binding site of the enzyme. As a result an enzyme-XMP-MPA complex is formed 
and IMPDH activity is inhibited (18-20). This inhibition is reversible (19). Treatment of 
cells with MPA results in inhibition of DNA synthesis and a G,-S phase block occurs 
(12,17,21,22) as a result of dGTP depletion. Furthermore, inhibitors of IMPDH induce 
differentiation of several lymphoblastic cell lines (23,24). 
In this study the effects of inhibition of IMPDH were studied in Molt F4, a human T-
lymphoblastic cell line. Human malignant lymphoblasts have a highly active purine de novo 
synthesis and purine salvage pathway (25,26). So, interference with guanine de novo syn-
thesis may have profound effects on cell growth, and cell viability in these cells. 
Materials and methods 
MPA and guanosine were purchased from Sigma Chemicals, USA. [8-14C]IMP (56 mCi/ 
mmol) was obtained from Amersham International, UK, and [l4C-carboxyl] orotic acid 
(52.5 mCi/mmol) from NEN, USA. 
The experiments were performed in Molt F4 cells, a human T-cell acute lymphoblastic leu-
kemia cell line. Cell culture procedures have been described in detail previously (27). 
For the determination of IMPDH activity 25,000 Molt F4 cells were required. IMPDH 
activity was determined by the radiochemical micro-assay method described earlier (28). 
Direct inhibition of IMPDH by MPA was determined by preincubation experiments. 
Several amounts of MPA were added to reaction buffer, containing 1.61 μιηοΐ Tris/HCl pH 
8.0 (Sigma Chemicals USA), 12.9 nmol reduced glutathione (GSH, Sigma Chemicals, 
USA), 3.23 nmol EDTA (Siegfried S.A., Switzerland), 3.23 nmol NAD+ (Sigma Chemi­
cals, USA) and 0.16 μΐηοΐ KCl (Merck, Germany). Two μ\ of this reaction mixture were 
added to the lyophilized cell lysates and pre-incubation was performed for 20 minutes at 
37°C. Hereafter, 8 μ\ of the above reaction mixture, but with radiolabelled IMP were 
added, to a final volume of 10 μΐ and incubation was performed for 60 minutes at 37°C. 
The end concentration of [8-14C]IMP was 2.9 nmol. The enzyme activity was determined by 
the method previously described (28). 
To determine cell growth, cell viability and nucleotide concentrations, logarithmically 
growing cells were seeded in a concentration of 0.2 χ 106 cells per ml, 24 h prior to the 
start of the experiments. MPA (0.5 and 1 μΜ) and guanosine (25 μΜ) were added as a sin­
gle dose in a small volume (1/100). Experimental procedures have been described elsewhere 
(2η. 
Endogenous nucleotides were extracted from 3 χ 10* viable cells by means of 0.4 M per­
chloric acid (PCA, BDH Chemicals Ltd, UK) extraction, and were determined by means of 
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separation by HPLC and monitored at a wavelength of 254 nro as described earlier (29). 
The concentrations were expressed as pmoles/10* viable cells. 
Medium nucleosides and bases were extracted with a final concentration of 0.4 M PCA 
from 0.5 ml medium and were determined by means of reverse-phase HPLC and monitored 
at a wavelength of 254 nm. Concentrations were expressed as ßmoles/L. 
The assay for determination of the PRPP concentration is based on the enzymic conversion 
of PRPP with [14C-carboxyl] orotic acid to 14C02 and uridine monophosphate and has been 
described earlier (30). 
Results 
The specific activity of IMPDH in Molt F4 human lymphoblasts without preincubation was 
2.0 ± 0.2 nmol.10"6 viable cells.h1 (mean ± SEM). As a result of pre-incubation IMPDH 
activity in the control dropped to 0.9 ± 0 . 1 nmol.10"* viable cells.h1. Pre-incubation of 
Molt F4 cell lysates with 0.1 μΜ MPA resulted in a decrease of IMPDH activity to 0.35 ± 
0.1 nmol.10"* viable cells.h1. Pretreatment with 0.5 μΜ MPA led to a reduction of enzyme 
activity to 0.27 ± 0.2 nmol.10"* viable cells.h1. 
Cytotoxicity of MPA in Molt F4 cells was concentration-dependent (Fig. 1). Treatment of 
cells with 0.5 μΜ MPA induced a severe inhibition of cell growth and a 50 % decrease of 
cell viability at 72 h. Under these conditions intracellular guanine nucleotide concentrations 
were depleted to approximately 40 % of control values (Table I). With 1 μΜ MPA inhibi­
tion of cell growth and cell viability was more severe (Fig. 1). However, depletion of gua­
nine nucleotides was almost similar (results not shown). 
No effect was observed on the intracellular adenine nucleotide concentration as a result of 
treatment of the cells with 0.5 μΜ MPA (Table I). Intracellular cytosine and uracil nucle­
otides increased slightly during the first 6 h after treatment (Table II). 
Furthermore, uridine and cytosine (in the form of cytidine) were excreted in the medium as 
a result of MPA treatment (Table ΙΠ). The intracellular PRPP concentration increased from 
90 pmol/106 viable cells in untreated cells to 180 pmol/10* viable cells 4 h after treatment 
with 0.5 μΜ MPA. 
Addition of a single dose of 25 μΜ guanosine partly prevented inhibition of cell growth by 
0.5 μΜ MPA during the first 24 h of the treatment. Hereafter, inhibition of cell growth still 
occurred (Fig. la). Cell viability remained at control values during the first 48 h of the 
treatment, but dropped to a value resembling that of cells treated with MPA alone after 72 h 
(Fig. lb). This MPA cytotoxicity, occurring despite the addition of guanosine once-only, 
can be attributed to depletion of intracellular guanine nucleotides, which occurred after 24 
h, resulting from exhaustion of guanosine in the culture medium (Table III). 
25 μΜ guanosine had to be supplemented daily to treatment with 0.5 μΜ MPA to prevent 
38 
Chapter 3 
viable cells (χ 10') 
2.00 
1.50 
1.00 
0.50 
0.00 
% viable cells 
100 
50 
25 
•*— eentrol 
• · - 0 6 μΜ MPA 
• · - 1 μΜ UPA 
*' SSuMguo 
one· 
-*- MPA * guo 
one« 
• · - MPA • QUO 
dâHy 
^ 
24 4B 72 
Time (h) 
Fig. 1. Cell growth (a) and cell viability (b) of Molt F4 cells after treatment with 0.5 μΜ MPA, 25 
μΜ guanosine, or a combination of both. Guanosine was added either alone, or in combination with 
0.5 μΜ MPA. Furthermore, effects of daily supplement of guanosine on cell growth and cell viability 
of untreated and MPA treated cells were assessed. The results of one experiment are shown. Similar 
results were obtained in two other experiments. 
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MPA cytotoxicity during the entire incubation period of 72 h (Fig. 1). Addition of guanosi-
ne resulted in an increase of intracellular guanine nucleotides and the presence of guanosine 
and guanine in the medium 2 and 6 h after each addition, as detected at 2, 6, 26 and 30 h 
(Table I). However, 24 h after addition, guanosine was consumed, since after 48 and 72 h 
intracellular guanine nucleotide concentrations were depleted again and no guanosine and 
guanine could be detected in the medium (Tables I and III) prior to the next daily supple­
ment of guanosine. 
Table III 
Concentrations of nucleosides and bases in culture medium of Molt F4 cells, treated with 0.5 μΜ 
MPA alone, or in combination with 25 μΜ guanosine (see further the legend to Table I). Concentra­
tions are expressed in μ/noles/L. Data of one representative experiment are shown (- means : below 
detection limit). 
Control 
MPA 
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dofly 
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Time 
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t - 0 
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-
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-
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Discussion 
In this study IMPDH activity is determined and the effects of its inhibition by MPA are stu­
died in Molt F4 human malignant lymphoblasts. 
A direct inhibition of IMPDH by MPA is demonstrated in pre-incubation experiments. 
However, as a result of pre-incubation, the enzyme activity in the control (without MPA) 
also decreases. This is possibly due to the absence of the substrate IMP during the pre­
incubation period of 20 min., since binding of IMP may exert a stabilizing effect on the 
enzyme in this in vitro setting. So, from these results it is clear that it is of importance to 
compare the results of the pre-incubation experiments only with controls which have 
undergone the same pre-incubation treatment. 
0.5 μΜ MPA induces cytotoxicity (Fig. 1), as a result of depletion of intracellular guanine 
nucleotides (Table I). Already 6 h after addition of MPA, depletion of guanine nucleotides 
is maximal. Since the guanine nucleotide pool is much smaller than the adenine nucleotide 
pool, depletion of guanine nucleotides may rapidly result in inhibition of cell growth and 
loss of cell viability (22). Inhibition of DNA synthesis after MPA treatment was reported 
earlier (12,17,21,22). 
The rapid increase of the PRPP concentration observed after treatment with 0.5 μΜ MPA 
may be explained by feedback-inhibition of PRPP amidotransferase (31) and of hypoxan-
thine-guanine phosphoribosyltransferase (32) by IMP. The PRPP concentration controls 
pyrimidine de novo synthesis (33), so the increase of PRPP accounts for the small increase 
of intracellular cytosine and uracil nucleotides and of extracellular cytosine and uracil 
nucleosides, observed early after the start of the MPA treatment (Tables Π and III). This 
effect is also observed when the purine de novo synthesis is inhibited by specific inhibitors 
(13,34-37). 
Guanosine was added to the incubations with MPA to determine whether depletion of intra­
cellular guanine nucleotides is the only cause for MPA cytotoxicity in Molt F4 cells. 
Exogenous guanosine is first converted into guanine by purine nucleoside Phosphorylase, 
and then into GMP by hypoxanthine-guanine phosphoribosyl transferase, an enzyme of the 
purine salvage route. Guanine is detectable in the medium after addition of guanosine (Table 
III). Addition of guanosine to incubation with 0.5 μΜ MPA prevents MPA cytotoxicity 
(Fig. 1), as described previously (5,12,21,38,39). However, a single addition of 25 μΜ 
guanosine to MPA treatment prevents depletion of intracellular guanine nucleotides only 
during the first 6 h of treatment (Table I). Furthermore, after 24 h no guanine or guanosine 
are present in the medium (Table III). This indicates a rapid consumption of guanosine by 
the purine salvage route. 
Daily supplements with 25 μΜ guanosine can maintain cell growth and cell viability at the 
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level of untreated cells. But still, after 24 h of incubation, prior to the next daily addition of 
guanosine, intracellular guanine nucleotides are depleted and extracellular guanosine and 
guanine are undetectable (Tables I and III)- So, guanosine consumption by the salvage path­
way in these cells is very rapid and 25 /tM guanosine is not sufficient to restore intracel­
lular guanine nucleotides during a period of 24 h. 
In conclusion, MPA induces cytotoxicity and inhibition of IMPDH activity in Molt F4 
human malignant lymphoblasts. Both cytotoxicity and depletion of intracellular guanine 
nucleotides could be prevented by addition of exogenous guanosine, indicating that depletion 
of guanine nucleotides is the only mechanism of cytotoxicity of MPA in these cells. 
References 
1. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes 
memorial lecture. Cancer Res., 43: 3466-3492, 1983. 
2. Pall, M.L. GTP: a central regulator of cellular anabolism. Curr.Top.Cell.Regul., 25: 1-20, 
1985. 
3. Bourne, H.R., Sanders, D.A., and McCormick, F. The GTPase superfamily: a conserved switch 
for diverse cell functions. Nature, 348: 125-132, 1990. 
4. Carlier, M-F. Guanosine-'5-triphosphate hydrolysis and tubulin polymerization. Molec.Cell. 
Biochem., 47: 97-113, 1982. 
5. Cass, CE., Lowe, J.k., Manchak, J.M., and Henderson, J.F. Biological effects of inhibition of 
guanine nucleotide synthesis by mycophenolic acid in cultured neuroblastoma cells. Cancer Res., 37: 
3314-3320, 1977. 
6. Weber, G. Enzymology of cancer cells. New Eng.J.Med., 296: 486-493, 1977. 
7. Camici, M., Tozzi, M.G., Allegrini, S., del Corso, Α., Sanfilippo, O., Diadone, M.G., de 
Marco, D., and Ipata, P.L. Purine salvage enzyme activities in normal and neoplastic human tissues. 
Cancer Biochem.Biophys., 11: 201-209, 1990. 
8. Jackson, R.C. and Weber, G. IMP dehydrogenase, an enzyme linked with proliferation and 
malignancy. Nature, 256: 331-333, 1975. 
9. Collait, F.R., Chubb, C.B., Mirkin, B.L., and Huberman, E. Increased inosine-5'-phosphate 
dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res., 52: 
5826-5828, 1992. 
10. Natsumeda, Y.( Ohno, S., Kawasaki, H., Konno, Y., Weber, G., and Suzuki, K. Two distinct 
cDNAs for human IMP dehydrogenase. J.Biol.Chem., 265: 5292-5295, 1990. 
11. Nagai, M., Natsumeda, Y., Konno, Y., Hoffman, R., Irino, S., and Weber, G. Selective 
up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in 
human leukemias. Cancer Res., 51: 3886-3890, 1991. 
12. Lee, H.J., Pawlak, K., Nguyen, B.T., Robins, R.K., and Sadee, W. Biochemical differences 
among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and 
selenazofurin, studied in mouse lymphoma cell culture. Cancer Res., 45: 5512-5520, 1985. 
13. Cohen, M.B. and Sadee, W. Contributions of the depletions of guanine and adenine nucleotides 
to the toxicity of purine starvation in the mouse Τ lymphoma cell. Cancer Res., 43: 1587-1591, 
1983. 
44 
Chapter 3 
14. Lui, M.S., Faderan, Μ.Α., Liepnieks, J.J., Natsumeda, Y., 01 ah, E., Jayaram, H.N., and 
Weber, G. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin 
(2-beU-D-ribofuranosylthiazole-4-carboxamide). J.Biol.Chem., 259: 5078-5082, 1984. 
15. Tricot, G.J., Jayaram, H.N., Lapis, E., Natsumeda, Y., Nichols, C.R., Kneebone, P., 
Heerema, N.. Weber, G., and Hoffman, R. Biochemically directed therapy of leukemia with 
tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. Cancer Res., 49: 
3696-3701, 1989. 
16. Engel, G., van Milczewski, K.E., Prokopek, D., and Teuber, M. Strain-specific synthesis of 
mycophenolic acid by Pénicillium roqueforti in blue-veined cheese. Appi.Environ.Microbiol., 43: 
1034-1040, 1982. 
17. Franklin, T.J. and Cook, J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. 
Biochem.J., 113: 515-524, 1969. 
18. Vernam, R., Meek, T.D., Hedstrom, L., and Wang, C.C. Purification, characterization, and 
kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus. Molec. 
Biochem.Parasitol., 24: 1-12, 1987. 
19. Hupe, D.J., Azzolina, B.A., and Behrens, N.D. IMP dehydrogenase from the intracellular 
parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid. J.Biol.Chem., 261: 
8363-8369, 1986. 
20. Hodges, S.D., Fung, E., McKay, D.J., Rénaux, В.S., and Snydes, F.F. Increased activity, 
amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant 
neuroblastoma cells. J.Biol.Chem., 264: 18137-18141, 1989. 
21. Cohen, M.B., Maybaum, J., and Sadee, W. Guanine nucleotide depletion and toxicity in mouse 
Τ lymphoma (S^9) cells. J.Biol.Chem., 256: 8713-8717, 1981. 
22. Duan, D-S. and Sadee, W. Distinct effects of adenine and guanine starvation on DNA synthesis 
associated with different pool sizes of nucleotide precursors. Cancer Res., 47: 4047-4051, 1987. 
23. Kiguchi, K., Collart, F.R., Henning-Chubb, C, and Huberman, E. Cell differentiation and 
altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by 
mycophenolic acid and tiazofurin. Exp.Cell Res., 187: 47-53, 1990. 
24. Collart, F.R. and Huberman, E. Expression of IMP dehydrogenase in differentiating HL-60 
cells. Blood, 75: 570-576, 1990. 
25. Marijnen, Y.M.T., de Korte, D., Haverkort, W.A., den Breejen, E.J.S., van Gennip, A.H., 
and Roos, D. Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 
'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells. 
Biochim.Biophys.Acta, 70/2: 148-155, 1989. 
26. Bökkerink, J.P.M., De Abreu, R.A., Bakker, M.A.H., Hulscher, T.W., van Baal, J.M., 
Schretlen, E.D.A.M., and de Bruyn, C.H.M.M. Effects of methotrexate on purine and pyrimidine 
metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. 
Biochem.Pharmacol., 37: 2329-2338, 1988. 
27. Stet, E.H., De Abreu, R.A., Janssen, Y.P.G., Bökkerink, J.P.M., and Trijbels, J.M.F. A 
biochemical basis for synergism of 6-mercaptopurine and mycophenolic acid in Molt F4, a human 
malignant T-lymphoblastic cell line. Biochim.Biophys.Acta, 1180: 277-282, 1993. 
28. Stet, E.H., De Abreu, R.A., Janssen, Y.P.G., Bökkerink, J.P.M., and Trijbels, J.M.F. 6-
mercaptopurine metabolism in two leukemie cell lines. Adv.Exp.Med.Biol., 309A: 83-89, 1991. 
29. De Abreu, R.A., van Baal, J.M., and Bakkeren, J.A.J.M. High-performance liquid chromato-
graphic assay for identification and quantitation of nucleotides in lymphocytes and malignant 
lymphoblasts. J.Chromatogr., 227: 45-52, 1982. 
45 
Chapter 3 
30. Vogt, M.H.J., Stet, E.H., De Abreu, R.A., Bökkerink, J.P.M., Lambooy, L.H.J., and Trijbels, 
J.M.F. The importance of methylthio-IMP for 6-methylmercaptopurine ribonucleoside (MeMPR) 
cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim.Biophys.Acta, 1181: 189-194, 
1993. 
31. Hill, D.L. and Bennett, L.L.Jr. Purification and properties of 5-phosphoribosyl pyrophosphate 
amidotransferase from adenocarcinoma 755 cells. Biochem., 8: 122-130, 1969. 
32. Hill, D.L. Hypoxanthine phosphoribosyltransferase and guanine metabolism of adenocarcinoma 
755 cells. Biochem.Pharmacol., 19: 545-557, 1970. 
33. Skaper, S.D., O'Brien, W.E., and Schafer, I.A. The influence of ammonia on purine and 
pyrimidine nucleotide biosynthesis in rat liver and brain in vitro. Biochem.J., 172: 457-464, 1978. 
34. Warnick, T.C. and Paterson, A.R.P. Effect of methylthioinosine on nucleotide concentrations in 
L5178Y cells. Cancer Res., 33: 1711-1715, 1973. 
35. Nelson, J.Α., Carpenter, J.W., Rose, L.M., and Adamson, D.J. Mechanisms of action of 
6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res., 35: 2872-2878, 1975. 
36. Woods, R.A., Henderson, R.M., and Henderson, J.F. Consequences of inhibition of purine 
biosynthesis de novo by 6-methylmercaptopurine ribonucleoside in cultured lymphoma L5178Y 
cells. Eur.J.Cancer, 14: 765-770, 1978. 
37. Sokoloski, J.A. and Salterelli, A.C. Inhibition of mannose incorporation into glycoproteins and 
dolichol-linked intermediates of sarcoma 180 cells by 6-methylmercaptopurine ribonucleoside. 
Int.J.Cancer, 39: 764-768, 1987. 
38. Sokoloski, J.Α., Blair, O.C., and Sartorelli, A.C. Alterations in glycoprotein synthesis and 
guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced 
by inhibitors of inosine 5'-phosphate dehydrogenase. Cancer Res., 46: 2314-2318, 1986. 
39. Dayton, J.S., Turka, L.A., Thompson, G.B., and Mitchell, B.S. Comparison of the effects of 
mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on Τ lymphocyte 
proliferation and purine ribonucleotide metabolism. Mol.Pharmacol., 41: 671-676, 1992. 
CHAPTER 4 
A BIOCHEMICAL BASIS FOR SYNERGISM OF 
6-MERCAPTOPURINE AND MYCOPHENOLIC ACID IN 
MOLT F4, A HUMAN MALIGNANT T-LYMPHOBLASTIC 
CELL LINE. 
Elisabet H. Stet, Ronney A. De Abreu, Yvonne P.G. Janssen, Jos P.M. Bökkerink, 
Frans J.M. Trijbels. 
Publication in: Biochimica Biophysica Acta 1180 (1993) 277-282. 
47 
Chapter 4 
A biochemical basis for synergism of 6-mercaptopurine and mycophenolic 
acid in Molt F4, a human malignant T-lymphoblastic 
cell line 
Summary 
6-Mercaptopurine (6MP) cytotoxicity was studied in Molt F4 cells, a T-cell acute lympho­
blastic leukemia (ALL) cell line. The effects on cytotoxicity were concentration-dependent. 
Measurements of intracellular thionucleotide intermediates of 6MP demonstrated a rapid rise 
of thio-IMP (tIMP) levels and subsequently a rapid decrease. Thio-GMP (tGMP) and 
methyl-thio-IMP (Me-tIMP) appeared later in time, and persisted longer. Mycophenolic acid 
(MPA), a specific inhibitor of IMP dehydrogenase (IMPDH), was used to inhibit the con­
version of tIMP into tGMP, thereby decreasing the incorporation of 6MP into DNA. A syn­
ergistic effect on cell viability and cell growth was observed when cells were treated with a 
combination of 2 μΜ 6MP and 0.5 μΜ MPA. Also, intracellular Me-tIMP increased 5 
times with the combination. Based on the increase of Me-tIMP concentration and the 
observed synergism between 6MP and MPA, we conclude that methylation of tIMP into 
Me-tIMP is an important alternative route for 6MP cytotoxicity. 
Introduction 
6-Mercaptopurine (6MP) is an analogue of the purine base hypoxanthine. It exhibits an 
antileukemic activity in vitro and in vivo (1) and is commonly used in the maintenance 
treatment of children with acute lymphoblastic leukemia (ALL), in combination with metho­
trexate (MTX). 
The first step of 6MP metabolism is intracellular uptake and conversion into thio-IMP 
(tIMP) by the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (2-4). A 
co-substrate for this reaction is phosphoribosyl pyrophosphate (PRPP). tIMP can be further 
metabolized by two pathways (see Scheme I). 
First, tIMP can be converted into thioguanine nucleotides by enzymes of the purine 
interconversion pathway (3,5,6). The key enzyme in this route is IMP dehydrogenase 
(IMPDH) (7,8). Thioguanine nucleotides can be incorporated into RNA and in particulary 
into DNA (5,9,10). Incorporation of thioguanine nucleotides into DNA results in delayed 
cytotoxicity by inhibition of transcription of DNA and by induction of DNA damage (11-
13), such as single strand breaks and protein cross-links (14,15). Secondly, tIMP can be 
methylated by the enzyme thiopurine methyltransferase (TPMT) into methyl-tIMP (Me-
tIMP) (4,16). Me-tIMP is a strong inhibitor of the first step in the purine de novo synthesis 
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Scheme I. 6-mercaptopurine metabolism 
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(1) Hypoxanthine-guanine phosphoribosyl transferase (HGPRT); (2) IMP-dehydrogenase (IMPDH); 
(3) Ihiopurine methyltransferase ÇTPMT)synthesis (19,20). 
(PDNS): PRPP amidotransferase (4,17,18). Inhibition of the PDNS also leads to cyto-
toxicity, as a result of decreased formation of purine nucleotides for DNA and RNA 
synthesis (19,20). 
Knowledge of the biochemical pathways leading to 6MP cytotoxicity is necessary for un-
derstanding of the therapeutic results of 6MP administration in patients with ALL. 
In this study, the significance of the methylation route for 6MP cytotoxicity is investigated 
in Molt F4, a human malignant T-lymphoblastic cell line. For this purpose IMPDH, the 
rate-limiting enzyme in the purine interconversion route was inhibited by mycophenolic acid 
(MPA), a specific inhibitor of this enzyme (21-24). 
Our studies indicate the importance of Me-tIMP for 6MP cytotoxicity, as demonstrated by a 
synergistic effect on cell growth and cell viability, with concurrent increase of Me-tIMP and 
a decreased formation of tGMP after simultaneous administration of 6MP and MPA. 
Materials and methods 
The experiments were performed with Molt F4 cells, a T-cell acute lymphoblastic leukemia 
cell line. The cells were cultured in RPMI 1640 DM (Gibco, the Netherlands) supplemented 
with 10% non-dialyzed fetal calf serum (Gibco, Netherlands), 2 mM L-glutamine (Sigma 
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Chemicals, USA), 2 mM sodium pyruvate (BDH Chemicals Ltd, UK) and gentamicin/ 
streptomycin, thrice a week. Cell cultures were maintained in a 5% CO, humidified atmos­
phere at 37°C. The absence of mycoplasma contamination and the presence of marker anti­
gens on the cells were tested regularly. 
24 h prior to the start of the experiments, logarithmically growing cells were seeded in a 
concentration of 0.2 χ 10* cells per ml. 6MP (Wellcome, Netherlands), MPA (Sigma Che­
micals, USA) or a combination of both were added as a single dose in a small volume 
(1/100). During the experiments 2 mM glutamine was supplemented every 24 h, in order to 
prevent glutamine exhaustion of the medium (25). After incubation the cells were harvested 
and counted in a coulter counter. The cell viability was determined by means of trypan blue 
exclusion. Cell growth was determined by counting the cells and correcting cell number for 
cell viability. 
Endogenous nucleotides were extracted from 3 χ 10s viable cells by means of perchloric 
acid (PCA, BDH Chemicals Ltd, UK) extraction. The cells were centrifuged in an Eppen-
dorf centrifuge for 2 min. A volume of 150 μί 0.4 M PCA was added to the cell pellet and 
the suspension was kept on ice for 10 min. The samples were centrifuged for 2 min. and 
the supernatant was collected and neutralized with 4 M KH2P04. The samples were stored 
at -20°C until analysis. The nucleotide concentrations were determined by means of HPLC 
(26) at a wavelength of 254 nm. The concentrations were expressed as pmoles/104 viable 
cells. 
Thionucleotides were extracted from 107 viable cells. PCA-extraction was performed with 
150 μί 0.4 M PCA and 0.3 % dithiotreitol (DTT, Boehringer, Mannheim) to prevent oxida­
tion of the thio-group. The samples were prepared further as described above and were 
analyzed by HPLC. Thio-IMP and thio-GMP concentrations were determined at 320 nm and 
Me-tIMP at 290 nm. The concentrations were expressed as pmoles/104 viable cells. 
Results 
Both 6MP and MPA induced inhibition of cell growth and cytotoxicity (Fig. la,b). 6MP 
cytotoxicity was concentration dependent (data not shown). 
When the cells were treated with a combination of 2 μΜ 6MP and 0.5 μΜ MPA, a syner­
gistic effect on cell growth and cell viability was observed (Fig. la,b). When 10 μΜ 6MP 
was used instead of 2 μΜ, no synergistic effect on cell growth and cell viability could be 
demonstrated, as a result of the very high cytotoxicity of 10 μΜ 6MP (data not shown). 
The endogenous purine nucleotide pools of cells treated with 2 μΜ 6MP were reduced 
during the first 24 h (Table I), while pyrimidine nucleotide concentrations were elevated 
(data not shown). However, purine nucleotide levels were restored after 48 h. With 
10 μΜ 6MP, depletion of purine nucleotides was more severe and persisted during the 
entire incubation period of 72 h (Table I). 
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Fig. 1. Cell growth (la) and cell viability (lb) of Molt F4 cells after treatment with 2 μΜ 6MP, 0.5 
μΜ MPA or a combination of both. The results one experiment are shown. Similar results were 
obtained in four other experiments. 
When the cells were treated with 0.5 μΜ MPA the cellular guanine nucleotide pool decre­
ased within 2 h after the start of the incubation and persisted during the entire incubation 
period of 72 h (Table II). No effects were observed on the adenine nucleotide concentration. 
The decrease of guanine nucleotides after 6 h with the combination of 2 μΜ 6MP and 0.S 
μΜ MPA was more severe than with either drug alone (Tables I and II). After 48 h, 
however, the guanine nucleotide concentration in the cells treated with the combination re­
covered (Table I), while it remained depressed in cells treated with MPA alone (Table II). 
The adenine nucleotide concentration remained the same. 
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атоіеэ/10' cell» 
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Fig. 2. Thionucleotide contents of Molt F4 cells treated with 2 or 10 μΜ 6MP either alone or in 
combination with 0.5 μΜ MP A (expressed as pmoles/W viable cells; mean with standard error of 5 
independent experiments). (a):tlMP;(b):tGMP;(c):Me-tIMP. 
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With a combination of 10 μΜ 6MP and 0.5 μΜ MP A, nucleotide concentrations did not 
differ significantly from those observed with 10 μΜ 6MP alone (Table I). Only the deple­
tion of the guanine nucleotide pool persisted for a longer period of time. 
Intracellular formation of the thionucleotides tIMP, tGMP and Me-tIMP could be demonstr­
ated after treatment with 6MP (Fig. 2). With 2 μΜ 6MP, the tIMP concentration reached 
its maximum at 2-6 h after the start of the incubation (Fig. 2a), then it declined. tGMP 
(Fig. 2b) and Me-tIMP (Fig. 2c) concentrations steadily increased to much higher levels 
during the first 24 h and declined afterwards. 
After incubation with 10 μΜ 6MP, more tIMP was formed, and it remained at a higher 
level than with 2 μΜ 6MP (Fig. 2a). The level of Me-tIMP increased continuously during 
incubation with 10 μΜ 6MP to a level 10 times higher as compared to the level reached 
with 2 μΜ 6MP at 72 h (Fig. 2c). tGMP levels obtained after incubation with 10 μΜ 6MP 
were comparable to those obtained after treatment with 2 μΜ 6MP (Fig. 2b). 
Determination of thionucleotide concentrations of cells treated with a combination of 2 μΜ 
6MP and 0.5 μΜ MPA revealed a prolonged intracellular availability of tIMP as compared 
to 6MP alone (Fig. 2a). As a result of addition of MPA, the tGMP concentration increased 
less during the first 24 h as compared to 6MP alone (Fig. 2b). However, no differences 
could be observed thereafter. The Me-tIMP level was affected most by combination of 
Table II: Purine nucleotide contents of Molt F4 cells treated with 0.5 μΜ MPA, expressed as 
percentage of untreated cells (mean with standard error of 5 independent experiments). The purine 
nucleotide concentrations in Molt F4 cells before treatment are 4750 ± 640 and 890 ± 120 
pmoles/101 viable cells for adenine and guanine nucleotides, respectively. 
ADP + ATP GDP + GTP 
time (h) 2 98 ± 11 48 ± 8 
6 104 ± 22 57 ± 15 
24 84 ± 19 61 ± 20 
48 118 ± 2 2 80 ± 13 
72 85 ±19 69 ± 17 
2 μΜ 6MP and 0.5 μΜ MPA (Fig. 2c). It increased considerably as a result of addition of 
MPA. At 48 h the Me-tIMP concentration with the combination was 5 times as high as 
compared to 6MP alone. 
After combination of 10 μΜ 6MP and 0.5 μΜ MPA tIMP and tGMP levels were lower as 
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compared to 10 μΜ 6MP alone (Figs. 2a,b). The Me-tIMP concentration with the combi­
nation did not differ significantly from that with 10 μΜ 6MP alone. 
Discussion 
6MP cytotoxicity can be caused by incorporation of thioguanine nucleotides into DNA and 
RNA and by formation of Me-tIMP and subsequent inhibition of the PDNS (4,17,18). Molt 
F4 cells strongly depend on PDNS with regard to formation of purine nucleotides for DNA 
and RNA synthesis (27). Therefore, inhibition of the PDNS can contribute significantly to 
the cellular cytotoxicity of 6MP for this malignant lymphoblastic cell line. 
Inhibition of the PDNS by Me-tIMP results in accumulation of PRPP. The surplus of PRPP 
can be used for de novo synthesis of pyrimidine nucleotides (6,19,28,29-31). This is also 
demonstrated in this study, as uridine and cytidine nucleotides increase to 270 % and 160 % 
of control, respectively, after a 48-h incubation with 2 μΜ 6MP (data not shown). 
In cells treated with 2 μΜ 6MP formation of thionucleotides as well as Me-tIMP can be 
demonstrated (Fig. 2). The long persistence of Me-tIMP levels, associated with depletion of 
its precursor 6MP in the medium 6 h after the start of the treatment (32), indicates a long 
half-life of this metabolite (33). After treatment with 10 μΜ 6MP the tIMP concentration is 
over 10 times as high as compared to 2 μΜ 6MP at 6 h. In spite of this, tGMP concentra­
tions with 10 μΜ 6MP do not exceed those of cells treated with 2 μΜ 6MP. This may be 
caused by two phenomena. First, high concentrations of tIMP cause inhibition of IMPDH 
(4), and thus formation of tGMP. Secondly, because ATP is a cofactor for the enzyme 
GMP-synthetase, the severe depletion of the adenine nucleotide pool with 10 μΜ 6MP may 
lead to inhibition of this enzyme and thus a decreased formation of tGMP. Therefore, it is 
necessary to reassess the effects of low and high concentrations of 6MP on cell growth and 
cell viability. With 10 μΜ 6MP a tremendous amount of Me-tIMP is formed as compared 
to 2 μΜ 6MP (Fig. 2) and relatively less 6MP is incorporated into DNA, especially after 24 
h (32). Inhibition of the PDNS by Me-tIMP leads to a nearly complete cessation of RNA 
and DNA synthesis, especially after 48 h (32). Also, cytotoxicity with 10 μΜ 6MP beco­
mes apparent early after the start of the treatment, whereas 2 μΜ 6MP hardly affects cell 
viability at that time. These observations lead to the conclusion that during treatment with 
high concentrations of 6MP, the methylation route is the most important mechanism for 
6MP cytotoxicity, whereas with lower concentrations of 6MP incorporation into DNA leads 
to delayed cytotoxicity after 48 h of incubation (5). 
Inhibition of IMPDH by MPA is especially cytotoxic for tumor cells (30). IMPDH was 
shown to have a higher activity in tumor cells as compared to normal cells (34), probably as 
a response to the high purine nucleotide need of tumor cells, necessary for DNA and RNA 
synthesis. In Molt F4 cells depletion of guanine nucleotides is already observed 2 h after 
addition of MPA (Table Π). These results are similar with those obtained in other studies 
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(35-37). 
The synergistic effects on cell growth and cell viability (Fig. 1) by the combination of 2 μΜ. 
6MP and 0.5 μΜ MPA clearly confirm the importance of the methylation route for 6MP 
cytotoxicity. As a result of the inhibition of IMPDH by MPA, more tIMP is available for 
methylation into Me-tIMP. Moreover, the increase of Me-tIMP concentration resulting from 
combination of both drugs leads to enhanced inhibition of PDNS, causing a more severe de­
pletion of purine nucleotides, especially of guanine nucleotides (Table I). 
The results of our studies are in contrast with the studies of Lennard et al. (38,39), who 
claim that methylation of tIMP into Me-tIMP is a detoxification pathway for 6MP cytotoxi­
city. In patients as a whole this may well be true, but with respect to the cellular level Me-
tIMP may have an additional effect on 6MP cytotoxicity. Their studies were performed in 
red blood cells, which lack an active PDNS and DNA synthesis, in contrast to malignant 
lymphoblasts. Because malignant lymphoblasts are the ultimate target for 6MP cytotoxicity 
in the treatment of ALL, Molt F4 human malignant lymphoblasts are a better model system 
to study the biochemical route for 6MP cytotoxicity. Another reason for underestimating the 
role of Me-tIMP for 6MP cytotoxicity may be that in patients the bioavailability of orally 
administered 6MP may be too low (40,41) to result in adequate Me-tIMP levels in red 
blood cells and peripheral lymphocytes. 
In conclusion, the methylation pathway of 6MP is important for cytotoxicity in Molt F4 
malignant human lymphoblasts. Synergism with respect to cytotoxicity is observed under 
conditions where an elevation of Me-tIMP concentration is measured and incorporation of 
6MP into DNA is at least partly blocked by MPA. 
References 
1. McCormack, J.J. and Johns, D.G. Purine Antimetabolites. In: Chabner B.A. (ed.), Pharmaco­
logic Principles of Cancer Treatment, pp. 213-227. Philadelphia: Saunders, 1982. 
2. Broekman, R.W. Aspects of mercaptopurine inhibition and resistance. Cancer Res., 23: 
1191-1201, 1963. 
3. Uchida, M., Nakamura, T., and Uchino, H. Conversion of 6-mercaptopurine to 6-thioguanylic 
acid in L1210 cells and human leukemia cells. Jpn.J.Cancer Res., 76: 124-130, 1985. 
4. Elion, G.B. Biochemistry and pharmacology of purine analogues. Fed.Proceed., 26: 898-904, 
1967. 
5. Tidd, D.M. and Paterson, A.R.P. A biochemical mechanism for the delayed cytotoxic reaction 
of 6-mercaptopurine. Cancer Res., 34: 738-746, 1974. 
6. Nelson, J.Α., Carpenter, J.W., Rose, L.M., and Adamson, D.J. Mechanisms of action of 
6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res., 35: 2872-2878, 1975. 
7. Weber, G., Olah, E., Lui, M.S., Kizaki, H., Tzeng, D.Y., and Takeda, E. Biochemical 
commitment to replication in cancer cells. Adv.Enzym.Regul., 18: 3-26, 1980. 
8. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy: G.H.A. Clowes 
memorial lecture. Cancer Res., 43: 3466-3492, 1983. 
56 
Chapter 4 
9. Tidd, D.M. and Paterson, A.R.P. Distinction between inhibition of purine nucleotide synthesis 
and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res., 34: 733-737, 1974. 
10. Scannet, J.P. and Hitchings, G.H. Thioguanine in deoxyribonucleic acid from tumors of 
6-mercaptopurine-treated mice (31210). Proc.Soc.Exp.Biol.Med., 722: 627-629, 1966. 
11. Maybaum, J. and Mandel, H.G. Differential chromatid damage induced by 6-thioguanine in 
CHO cells. Exp.Cell Res., 135: 465^68, 1981. 
12. Maybaum, J. and Mandel, H.G. Unilateral chromatid damage: a new basis for 6-thioguanine 
cytotoxicity. Cancer Res., 43: 3852-3856, 1983. 
13. Bod ell, W.J. Molecular dosimetry of sister chromatid exchange induction in 9L cells treated 
with 6-thioguanine. Mutagen., 6: 175-177, 1991. 
14. Christie, N.T., Drake, S., Meyn, R.E., and Nelson, J.A. 6-Thioguanine-induced DNA damage 
as a determinant of cytotoxicity in cultured chinese hamster ovary cells. Cancer Res., 44: 
3665-3671, 1984. 
15. Covey, J.M., D'Incaici, M., and Kohn, K.W. Production of DNA-protein crosslinks (DPC) by 
6-thioguanine (TG) and 2'-deoxy-6-thioguanosine (TGdR) in L1210 cells in vitro. 
Proc.Am.Assoc.Cancer Res., 27: 17, 1986. 
16. Remy, C.N. Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmeth-
ionine transmethylase and catabolism in mammalian tissues. J.Biol.Chem., 238: 1078-1084, 1963. 
17. McCollister, R.J., Gilbert, W.R., Ashton, D.M., and Wijngaarden, J.B. Pseudofeedback 
inhibition of purine synthesis by 6-mercaptopurine ribonucleotide and other purine analogues. 
J.Biol.Chem., 239: 1560-1563, 1964. 
18. Bennett, L.L.Jr. and Allan, P.W. Formation and significance of 6-methylthiopurine ribonucleo­
tide as a metabolite of 6-mercaptopurine. Cancer Res., 31: 152-158, 1971. 
19. Warnick, T.C. and Paterson, A.R.P. Effect of methylthioinosine on nucleotide concentrations in 
L5178Y cells. Cancer Res., 33: 1711-1715, 1973. 
20. Bennett, L.L.Jr. and Adamson, D.J. Reversal of growth inhibitory effects of 6-methylthiopurine 
ribonucleoside. Biochem.Pharmacol., 19: 2172-2176, 1970. 
21. Verham, R., Meek, T.D., Hedstrom, L., and Wang, C.C. Purification, characterization, and 
kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus. Molec. 
Biochem.Parasitol., 24: 1-12, 1987. 
22. Hupe, D.J., Azzolina, B.A., and Behrens, N.D. IMP Dehydrogenase from the intracellular 
parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid. J.Biol.Chem., 261: 
8363-8369, 1986. 
23. Kuttan, R. and Saunders, P. Inhibitors of inosinate dehydrogenase. Biochem.Int., 2: 211-218, 
1987. 
24. Franklin, T.J. and Cook, J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. 
Biochem.J., 113: 515-524, 1969. 
25. Вбккегіпк, J.P.M., Bakker, M.A.H., Hulscher, T.W., De Abreu, R.A., Schretlen, E.D.A.M., 
van Laarhoven, J.R.P.M., and de Bruyn, C.H.M.M. Sequence-, time- and dose-dependent 
synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem. 
Pharmacol., 35: 3549-3555, 1986. 
26. De Abreu, R.A., van Baal, J.M., and Bakkeren, J.A.J.M. High-performance liquid chromato­
graphic assay for identification and quantitation of nucleotides in lymphocytes and malignant 
lymphoblasts. J.Chromatogr., 227: 45-52, 1982. 
57 
Chapter 4 
27. Marijnen, Y.M.T., de Korte, D., Haverkort, W.A., den Breejen, E.J.S., van Gennip, A.H., 
and Roos, D. Studies on the incorporation of precursors into purine and pyrimidine nucleotides via 
'de novo' and 'salvage' pathways in normal lymphocytes and lymphoblastic cell-line cells. 
Biochim.Biophys.Acta, 1012: 148-155, 1989. 
28. Skaper, S.D., O'Brien, W.E., and Schafer, I.A. The influence of ammonia on purine and 
pyrimidine nucleotide biosynthesis in rat liver and brain in vitro. Biochem.J., 172: 457-464, 1978. 
29. Woods, R.A., Henderson, R.M., and Henderson, J.F. Consequences of inhibition of purine 
biosynthesis de novo by 6-methylmercaptopurine ribonucleoside in cultured lymphoma L5178Y 
cells. Eur.J.Cancer, 14: 765-770, 1978. 
30. Cohen, M.B. and Sadee, W. Contributions of the depletions of guanine and adenine nucleotides 
to the toxicity of purine starvation in the mouse Τ lymphoma cell. Cancer Res., 43: 1587-1591, 
1983. 
31. Sokoloski, J.A. and Sartorelli, A.C. Inhibition of mannose incorporation into glycoproteins and 
dolichol-linked intermediates of sarcoma 180 cells by 6-methylmercaptopurine ribonucleoside. 
IntJ.Cancer, 39: 764-768, 1987. 
32. Bökkerink, J.P.M. Thesis. 1987. 
33. Loo, T.L., Luce, J.K., Sullivan, M.P., and Frei III, E. Clinical Pharmacologic observations on 
6-mercaptopurine and б-methylthiopurine ribonucleoside. Clin.Pharmacol.Ther., ft 180-194, 1967. 
34. Jackson, R.C. and Weber, G. IMP dehydrogenase, an enzyme linked with proliferation and 
malignancy. Nature, 256: 331-333, 1975. 
35. Lowe, J.k., Brox, L., and Henderson, J.F. Consequences of inhibition of guanine nucleotide 
synthesis by mycophenolic acid and virazole. Cancer Res., 37: 736-743, 1977. 
36. Ullman, B. Characterization of mutant murine lymphoma cells with altered inosinate dehydroge­
nase activities. J.Biol.Chem., 258: 523-528, 1983. 
37. Lee, H.J., Pawlak, K., Nguyen, B.T., Robins, R.K., and Sadee, W. Biochemical differences 
among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and 
selenazofurin, studied in mouse lymphoma cell culture. Cancer Res., 45: 5512-5520, 1985. 
38. Lennard, L., van Loon, J.Α., Lilleyman, J.S., and Weinshilboum, R.M. Thiopurine pharmaco­
kinetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thiogua-
nine nucleotide concentrations. Clin.Pharmacol.Ther., 41: 18-25, 1987. 
39. Lennard, L., Lilleyman, J.S., van Loon, J.Α., and Weinshilboum, R.M. Genetic variation in 
response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet, 336: 225-229, 
1990. 
40. Schouten, T.J., De Abreu, R.A., De Bniijn, С.H.M.M., van der Kleijn, E., Oosterbaan, 
M.J.M., Schretlen, E.D.A.M., and de Vaan, G.A.M. 6-Mercaptopurine: pharmacokinetics in 
animals and preliminary results in children. Adv.Exp.Med.Biol., 165B: 367-370, 1984. 
41. Zimm, S., Collins, J.M., Riccardi, R., O'Neill, D., Narang, P.K., Chabner, В., and Poplack, 
D.G. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute 
lymphoblastic leukemia being optimally delivered. N.Eng.J.Med., 308: 1005-1009, 1983. 
58 
CHAPTER 5 
THE IMPORTANCE OF METHYLTHIO-IMP FOR 
METHYLMERCAPTOPURINE RIBONUCLEOSIDE (ME-MPR) 
CYTOTOXICITY IN MOLT F4 HUMAN MALIGNANT T-
LYMPHOBLASTS. 
Mario H.J. Vogt, Elisabet H. Stet, Ronney A. De Abreu, 
Jos P.M. Bökkerink, Lambert H.J. Lambooy, Frans J.M. Trijbels. 
Publication in: Biochimica Biophysica Acta 1181 (1993), 189-194. 
59 
Chapter 5 
The importance of methylthio-IMP for methylmercaptopurine 
ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-
lymphoblasts 
Summary 
The importance of methyl-thioIMP (Me-tIMP) formation for methylmercaptopurine ribonu­
cleoside (Me-MPR) cytotoxicity was studied in Molt F4 cells. Cytotoxicity of Me-MPR is 
caused by Me-tIMP formation with concomitant inhibition of purine de novo synthesis. 
Inhibition of purine de novo synthesis resulted in decreased purine nucleotide levels and 
enhanced 5-phosphoribosyl-l -pyrophosphate (PRPP) levels, with concurrent increased pyri-
midine nucleotide levels. The Me-tIMP concentration increased proportionally with the 
concentration of Me-MPR. High Me-tIMP concentration also caused inhibition of PRPP 
synthesis. Maximal accumulation of PRPP thus occurred at low Me-MPR concentrations. 
As little as 0.2 μΜ Me-MPR resulted already after 2 h in maximal inhibition of formation 
of adenine and guanine nucleotides, caused by inhibition of purine de novo synthesis by 
Me-tIMP. Under these circumstances increased intracellular PRPP concentrations could be 
demonstrated, resulting in increased levels of pyrimidine nucleotides. So, in Molt F4 cells, 
formation of Me-tIMP from Me-MPR results in cytotoxicity by inhibition of purine de novo 
synthesis. 
Introduction 
Methyl-thioIMP (Me-tIMP) is a strong inhibitor of purine de novo synthesis at the level of 
the enzyme phosphoribosylpyrophosphate amidotransferase (scheme 1) (1-3), causing cyto­
toxicity and especially inhibition of cell growth, as a result of decreased formation of purine 
nucleotides for DNA and RNA synthesis (4-7). 
The cytotoxicity of methylmercaptopurine ribonucleoside (Me-MPR) is caused by its con­
version into Me-tIMP (5,8,9). Me-MPR can be converted into Me-tIMP by the enzyme ade­
nosine kinase with ATP as co-substrate (8,10-12) (scheme 1). Me-MPR is a potent inhibitor 
of the growth of several mouse tumors and of human tumor cells grown in culture (13,14). 
Incubation of a variety of tumor cell lines with Me-MPR leads to decreased purine de novo 
synthesis (5,15,16), resulting in decreased purine nucleotide levels, increased concentrations 
of 5-phosphoribosyl-l-pyrophosphate (PRPP) (15,17,18) and enhanced pyrimidine nucleo­
tide levels (4,16). 
Me-tIMP formation is also important for cytotoxicity of 6-mercaptopurine (6MP), an ana­
logue of hypoxanthine (7). 6MP is converted into thio-IMP (tIMP) by the enzyme hypoxan-
thine-guanine phosphoribosyltransferase with PRPP as co-substrate (1,19,20). Further 
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Scheme 1. Purine metabolism. 
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(1) Adenosine kinase (AK); (2) Hypoxanthine-guanine phosphoribosyl transferase (HGPRT); (3) 
Thiopurine methyltransferase (TPMT); (4) Phosphoribosylpyrophosphate amidotransferase; (5) 
Phosphoribosylpyrophosphate synthetase (PRPPs). 
conversion of tIMP occurs by two routes. Firstly, t-IMP can be converted into thioguanine 
nucleotides (20-22). Subsequently, these thioguanine nucleotides can be incorporated into 
RNA or DNA (6,21,23,24) which results in delayed cytotoxicity (21,25). Secondly, ÜMP 
can be methylated by thiopurine methyltransferase into Me-tIMP, which inhibits purine de 
novo synthesis (1,26). Both metabolic routes of 6MP are important for cytotoxicity (7). 
6MP exhibits an antileukemic activity in vitro and in vivo (27) and is commonly used in the 
maintenance treatment of children with acute lymphoblastic leukemia in combination with 
methotrexate. 
In this study, the effects of Me-tIMP on cell growth and cell viability, PRPP levels and 
purine and pyrimidine nucleotide concentrations are investigated in Molt F4 cells, a human 
T-lymphoblastic cell line, by treating the cells with various concentrations of Me-MPR or 
6MP. 
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Materiate and methods 
6MP was purchased from Wellcome, the Netherlands; Me-MPR, PRPP (sodium salt), the 
yeast orotidine-5-phosphate ribosyltransferase/orotidine-S-phosphate decarboxylase were 
obtained from Sigma Chemicals, USA. ["C-Carboxyl] orotic acid (S2.5 mCi/mmol) was 
obtained from NEN Products, MA, USA. 
The studies were performed with Molt F4 cells, a T-cell acute lymphoblastic leukemia cell 
line. All experiments were started with an initial concentration of 0.2 χ 10* cells/ml 24 h 
before addition of the drugs. Me-MPR and 6MP were added as a single dose in a small vol­
ume (1/100). Conditions for cell culture and experimental procedures have been described 
earlier (7). 
Determination of endogenous nucleotides and Me-tIMP: 
Endogenous nucleotides (di- and triphosphates) and Me-tIMP were determined by means of 
HPLC (7,28). The nucleotide concentrations were determined at 254 nm and Me-tIMP at 
290 nm. Concentrations were expressed as pmoles/10* viable cells. 
PRPP assay: 
We used the assay for determination of PRPP as previously described (29-32), but with a 
few modifications. The PRPP concentration was determined by its enzymatic conversion 
with [I4C-carboxyI] orotic acid to form l 4C0 2 and uridine monophosphate. 
A 1.0 ml aliquot of cell suspension was centrifuged in an Eppendorf centrifuge for 2 min. 
The cell pellet was suspended in 2S0 μΐ 50 mM Tris-HCl (pH 7.4) containing 1 mM 
EDTA. After vortexing, the cells were lysed by sonification (Branson sonifier, 4 bursts of 
10 sec at 20% of maximal output) and vortexed again. 100 μΐ suspension (in duplicate) was 
transferred in a glass vial which was sealed with a rubber cap. 
Enzymes in this suspension were inactivated by heating for 45 sec in boiling water. After 
the heating step, the reaction was initiated by adding 10 μΐ orotidine-5-phosphate ribosyl-
transferase/orotidine-5-phosphate decarboxylase (7.7 mg/ml) in 25 mM MgCl2 solution, fol­
lowed by 5 μΐ 1.17 mM [,4C-carboxyl] orotic acid (17 mCi/mmol). Immediately afterwards, 
a second smaller vial, containing 0.7 ml hyamine, was inserted in the reaction vial and the 
vial was sealed again instantly. While shaking, the reaction was performed for 90 min at 
37°C and immediately stopped afterwards with 50 μ\ of 4 N HC104. Shaking was contin­
ued for 90 min to trap all 1 4C02 in the inner vial. The vial with hyamine was transferred to 
another glass vial containing 5 ml of Toluene Scintillator and the amount of trapped , 4 C0 2 
was counted in a liquid scintillation counter. 
Some PRPP was destroyed during the heating step. The mean recovery of standard PRPP 
solutions added to cell lysates was 88.0% (S.D. = 3.8, N = 11). So, a correction was 
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made for the percentage of PRPP lost during heating. The assay was linear between 50 
pmoles and 3000 pmoles (corr. coeff. : 0.9997, N = 7). 
Results 
When Molt F4 cells were incubated with various concentrations of Me-MPR, a concentra­
tion dependent inhibition of both cell growth and cell viability was observed (Figs. la,b). 
From 0.1 to 0.5 μΜ Me-MPR, cell growth and cell viability decreased with increasing 
concentration of Me-MPR. With 0.5 μΜ Me-MPR, cell growth exhibited a minimum of 15 
% of the control and cell viability about 60% of the control at 48 h of incubation. 
Maximal conversion of Me-MPR into Me-tIMP took place within the first 2 h (Table 1). 
Call growth 1% of controll . , 
Δ °1 
-О 0 2 
- , ОБ 
* * * " » * 10 
, 2 
24 4Β 
time (h) 
Cell viability (% of control) 
26 -
0 24 48 
time (h) 
Fig. 1. Cell growth (a) and cell viability φ) of Molt F4 cells after treatment with various concen­
trations Me-MPR (expressed as percentages of untreated cells; the results of one experiment are 
shown. Similar results were obtained in two other experiments). 
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Table I. Me-tlMP levels in Molt-F4 cells treated with various concentrations qfMe-MPR (expressed 
as pmoleslKf viable cells; median with range (between brackets) of3 independent experiments). 
time(h) 0.1 μΜ Me-MPR 0.2 μΜ Me-MPR 0.5 μΜ Me-MPR 2.0 μΜ Me-MPR 10 μΜ Me-MPR 
2 281 (275-359) 
6 271 (254-291) 
24 145(117-148) 
48 40 (39-42) 
560(514-596) 1130(1127-1234) 3264(2810-3377) 3922(3583-4469) 
520 (484-527) 1123 (1088-1706) 2431 (2381-2753) 4007 (3661-4007) 
437(386-450) 1170(1019-1170) 3406(3332^035) 4623(3434-5161) 
225(223-225) 1276(1165-1358) 3634(2902-3667) 4506(3504-4644) 
Adenine nuc le o l ide s(p mo le s/10'ce l ls ) 
G u a n i n e nuc leot idesfpmoles/10'ce l ls ) 
kfi 
ÍÍ.M. 
% I І 
Λ 
I I control 
WM 0 1 μΜ 
У77Л 0 2μΜ 
I Ι 0 6 μ Μ 
> ί 2μΜ 
^Ш 10 μΜ 
48 
time (h) 
Fig. 2. Adenine (a) and guanine (b) nucleotides (di- and triphosphates) of Molt F4 cells treated with 
various concentrations Me-MPR (expressed as pmoleslKf cells; mean with standard error of 3 inde­
pendent experiments). 
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PRPP (pmoles/10' cells) 
time (h) 
time (h) 
Cvtoslne nueleotldasfpmoles/1O'cells) 
с 
time (h) 
Fig. 3. PRPP levels (a) and uracil (b) and cytosine (c) nucleotides in Molt F4 cells treated with 
various concentrations Me-MPR (expressed as pmoles/Ш cells; mean with standard error of 3 
independent experiments). 
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The Me-tIMP concentration increased with increasing Me-MPR concentrations. However, 
with 10 μΜ Me-MPR a slightly higher increment was observed compared with 2 μΜ Me-
MPR after 2 h. Me-tIMP concentrations obtained with 0.1 μΜ and 0.2 μΜ Me-MPR 
reached a maximum at 2 h and decreased again after 6 h. With higher concentrations of 
Me-MPR the Me-tIMP concentrations remained at a high level during the whole incubation 
period. 
Adenine and guanine nucleotide concentrations decreased after treatment with Me-MPR 
(Figs. 2a,b). A minimal adenine nucleotide concentration of 30% of the control was already 
achieved with 0.2 μΜ Me-MPR after 6 h and no difference was observed with increasing 
concentrations of Me-MPR. Recovery of the adenine nucleotide concentration of cells, 
treated with 0.1 and 0.2 μΜ Me-MPR, appeared after 48 h. Guanine nucleotides exhibited a 
minimum of about 35% of control after 2 h, while the recovery appeared within 24 h. 
3000 
2000 
1000 
PRPPíDmoles/10'eells) 
Й\і 
• t L 
/ 
^•-^ 
. 1 1 
^ — - ^ ^ Τ 
- · 
χ 
ι 
1000 2000 3000 4000 
M«-tlMP (pmola«/10'cella) 
Fig. 4. PRPP levels as a function of Me-tIMP levels after 6 h of incubation with various concen­
trations of Me-MPR, derived from Table 1 and Fig. 3a. (mean of 3 independent experiments; Me-
tIMP concentrations were expressed as nmoleslKf cells; PRPP concentrations were expressed as 
nmoleslKf cells). 
Fig. 3a shows the effects of various concentrations of Me-MPR on intracellular PRPP levels 
in Molt F4 cells. PRPP levels rapidly increased after incubation with Me-MPR, especially 
at low concentrations of Me-MPR. Maximal accumulation of PRPP occurred at 6 h, with a 
25-fold increase of PRPP level after incubation with 0.2 μΜ Me-MPR. After an initial in­
crease of PRPP levels after incubation with 0.1 μΜ Me-MPR and to a lesser extent with 
0.2 μΜ Me-MPR, the PRPP concentration decreased after 6 h, whereas PRPP levels obtai-
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ned with higher Me-MPR concentrations hardly changed. In general, the changes in PRPP 
levels closely resembled that of pyrimidine nucleotide levels. Endogenous pyrimidine 
nucleotides increased with 0.1 to 0.5 μΜ Me-MPR (Figs. 3b,c). Maximal increments after 
2 h appeared with 0.1 μΜ Me-MPR. At this time uracil nucleotides increased to 200% and 
cytosine nucleotides to 160% of the control. With 0.1 μΜ and 0.2 μΜ Me-MPR the eleva­
ted pyrimidine nucleotide levels persisted during the entire incubation period of 48 h, 
whereas the levels after incubation with 0.S μΜ Me-MPR recovered to control values after 
48 h of incubation. 
Table 2. PRPP levels in Molt F4 cells treated with various concentrations 6MP (expressed as 
pmoleslKf cells; mean with standard error of 4 independent experiments). PRPP levels in untreated 
cells were: 108 ± 28 pmoleslKf cells. 
time(h) 
4 
8 
24 
48 
2 μΜ 6MP 
441 ± 56 
623 ± 113 
789 
1080 
10 μΜ 6MP 
454 ± 78 
527 ± 50 
126 
146 
Fig. 4 demonstrates the correlation between PRPP accumulation and Me-tIMP levels, mea­
sured after 6 h of incubation with various concentrations of Me-MPR (Table 1 and Fig. 3a). 
After an initial increase of intracellular PRPP concentration to a maximum at 500 pmoles 
Me-tIMP/10s viable cells, PRPP accumulation decreased with higher Me-tIMP concentra­
tions. 
Me-tIMP formation is also an important step for 6MP cytotoxicity (7,33). The effects of 
6MP on PRPP levels are demonstrated in table 2. With 2 μΜ 6MP a 6-fold increase in 
PRPP level within 8 h was followed by a slower increase during the remaining incubation 
period. Treatment of cells with 10 μΜ 6MP caused an initial 5-fold increment of PRPP 
levels within 8 h, followed by a decrease after 24 h to control values. 
Discussion 
In order to study the influence of Me-tIMP on cell growth, cell viability, nucleotide pools 
and PRPP levels, Molt F4 cells were incubated with various concentrations of Me-MPR. 
The effect of Me-MPR on cell growth was more severe than on cell viability (Figs. la,b). 
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Decreased cell growth and unaltered cell viability after treatment with 0.1 μΜ Me-MPR 
indicates that cell growth depends on an intact purine de novo synthesis in rapidly dividing 
malignant cells (34). 
The direct conversion of Me-MPR into Me-tIMP was demonstrated in Table 1, showing an 
almost maximal Me-tIMP formation for all Me-MPR concentrations at 2 h of incubation 
(16). The relatively small increment of Me-tIMP from 2 μΜ to 10 μΜ Me-MPR may be a 
consequence of depletion of ATP (Fig. 2a). As ATP is a co-substrate for the conversion of 
Me-MPR into Me-tIMP by adenosine kinase, depletion of ATP may lead to suboptimal acti­
vity of this enzyme. 
The decrease of Me-tIMP concentration with 0.1 μΜ Me-MPR after 24 and 48 h (Table 1) 
was accompanied by a decrease of PRPP levels (Fig. 3a), indicating that Me-tIMP indeed 
accounts for the increased PRPP levels. The lesser extent of PRPP accumulation with 
higher Me-MPR concentrations (Fig. 3a), associated with higher Me-tIMP concentrations 
(Table 1), might be explained by an inhibitory effect of Me-MPR on the synthesis of PRPP. 
This could also be demonstrated in Fig. 5, showing a decrease of PRPP levels with incre­
asing intracellular Me-tIMP levels above 500 pmol/106 cells. Yen et al. also described 
inhibition of PRPP synthetase with high concentrations of Me-MPR by the Me-MPR meta­
bolite, Me-tIMP, in human fibroblasts (35). Moreover, decrease of PRPP synthetase activity 
with increased Me-MPR concentrations could also be caused by the decreased availability of 
ATP, the co-substrate for PRPP synthetase. Firstly, ATP is consumed for the conversion of 
Me-MPR into Me-tIMP by adenosine kinase. Secondly, the inhibition of the purine de novo 
synthesis by Me-tIMP results in a concurrent decrease of ATP formation (Fig. 2a). So, with 
high concentrations of Me-MPR more ATP will be consumed and ATP formation will be 
inhibited more severely, resulting in less availability of ATP for PRPP synthesis. 
The depletion of adenine and guanine nucleotides (Figs. 2a,b) reflects the effect of Me-MPR 
on purine de novo synthesis (16). The more persistent decrease of adenine nucleotides com­
pared to guanine nucleotides is probably due to competitive inhibition of adenosine kinase 
by Me-MPR. As a result of this, conversion of adenosine into AMP and subsequently into 
ATP cannot occur optimally. In addition, purine precursors, e.g. from dead cells, become 
available for guanine nucleotide synthesis by the salvage pathway and purine interconver­
sion. 
Accumulation of PRPP, especially at low Me-MPR concentrations, caused an increase of 
pyrimidine nucleotide levels within 6 h of incubation with Me-MPR (Figs. 3b,c). This 
observation is in agreement with earlier observations (11),(12). The results of both purine 
nucleotides and PRPP levels, indicate that a maximal inhibition of the purine de novo 
synthesis is already achieved with 0.2 μΜ Me-MPR, corresponding with 500 pmoles Me-
tIMP/ 10s viable cells. Under these conditions PRPP levels are maximal and endogenous 
purine nucleotide levels are minimal (Fig. 4). 
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Incubation of cells with 6MP, another anticancer drug of which Me-tlMP is an active 
metabolite, also led to increased PRPP levels (Table 2). Me-tIMP, formed after methylation 
of thio-IMP by thiopurine methyltransferase, is responsible for this elevation of PRPP 
levels. Previous research showed that with 6MP maximal Me-tIMP concentration occurred 
after 24 h (7). This is in contrast with already maximal levels of Me-tIMP after 2 h of 
incubation with Me-MPR (Table 1). These data may indicate that the methylation enzyme 
thiopurine methyltransferase has to be induced, to result in maximal Me-tIMP concentrati­
ons at later times after incubation with 6MP, as has been described in literature (36,37). 
The increase of PRPP levels with 2 μΜ 6MP up to 48 h confirm this phenomenon (Table 
2). 
The decline of PRPP levels to control values after prolonged incubation with 10 μΜ 6MP, 
despite of the increase of Me-tIMP concentration (7), seems to be in contrast. However, 
under these conditions reutilization of nucleotide precursors, that become available from 
dead cells as a consequence of the high cytotoxicity of 10 μΜ 6MP, occurs. This is asso­
ciated with PRPP consumption. Moreover, inhibition of PRPP synthetase by high concentra­
tions of Me-tIMP may result in the observed decrease of the PRPP levels to control values. 
In conclusion, Me-tIMP is a potent inducer of inhibition of both cell growth and cell via­
bility in Molt F4 cells, which exhibit a highly active purine de novo synthesis. Therefore, 
Me-tIMP is an important metabolite for Me-MPR and 6MP cytotoxicity in cells with an 
active purine de novo synthesis. 
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Reversal of 6-mercaptopurine and 6- methylmercaptopurine ribonucleoside 
cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 
human malignant T-Iymphoblasts 
Summary 
Cytotoxicity of 6-mercaptopurine (6MP) and 6-methylmercaptopurine ribonucleoside (Me-
MPR) was studied in Molt F4 human malignant lymphoblasts. Both drugs are converted 
into methyl-thioIMP (Me-tIMP), which inhibits purine de novo synthesis. Addition of 
amidoimidazole carboxamide ribonucleoside (AICAR) circumvented inhibition of purine de 
novo synthesis, and thus partly prevented 6MP and Me-MPR cytotoxicity. Purine nucleo-
tides, and especially adenine nucleotides recovered by addition of AICAR. Under these 
conditions, Me-tIMP formation decreased. The results of this study indicate that formation 
of Me-tIMP may be important for 6MP cytotoxicity in Molt F4 cells. These data suggest 
that depletion of adenine nucleotides is the main cause for Me-tIMP cytotoxicity. 
Introduction 
6-Mercaptopurine (6MP), an analogue of the purine base hypoxanthine, is used in the main-
tenance treatment of children with acute lymphoblastic leukemia. The first step in 6MP 
cytotoxicity is conversion into thioIMP (tIMP) (1,2). tIMP can be metabolized by two path-
ways. First, it is converted into thioguanine nucleotides, which can be incorporated into the 
RNA and DNA of the cells, leading to DNA-damage and delayed cytotoxicity (3,4). 
Second, it is methylated into methyl-thioIMP (Me-tIMP) by the enzyme thiopurine methyl-
transferase (EC 2.1.1.67) (1,5). Since Me-tIMP is a strong inhibitor of purine de novo 
synthesis (6-8) it induces cytotoxicity by depletion of purine ribonucleotides. 
In the present study the importance of Me-tIMP for 6MP cytotoxicity was examined in 
more detail. Amidoimidazole carboxamide ribonucleoside (AICAR), an intermediate of puri-
ne de novo synthesis distal to the site where Me-tIMP exerts its inhibiting effect, was used 
to circumvent inhibition of this route by Me-tIMP. AICAR is phosphorylated into AICAR 
monophosphate by adenosine kinase (AK, EC 2.7.1.20) (9,10) and can enter purine de novo 
synthesis in this form. Me-tIMP cytotoxicity was examined more specifically using 
6-methylmercaptopurine ribonucleoside (Me-MPR). This is also converted by AK (11) into 
Me-tIMP. Again AICAR was used to prevent inhibition of purine de novo synthesis. 
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Materials and Methods 
Mycophenolic acid (MPA), Me-MPR and AICAR were purchased from the Sigma Chemi­
cal Co. (St. Louis, MO, U.S.A.); 6MP from Wellcome (Utrecht, The Netherlands). The 
experiments were performed with Molt F4, a human T-cell acute lymphoblastic leukemia 
cell line. Conditions for cell culture and experimental procedures have been described in 
detail previously (12). 
Endogenous nucleotides (di- and triphosphates) were determined in 3 χ 10* viable cells, 
according to the method described earlier (13), and were measured at a wavelength of 254 
nm. Nucleotide concentrations were expressed as pmoles/106 viable cells. Thionucleotides 
were extracted from 107 viable cells, according to the procedure described earlier (12). 
ÜMP and tGMP were determined at 320 nm. Me-tIMP was measured at 290 nm. Concen-
trations were expressed as pmoles/10* viable cells. 
Results 
Treatment of Molt F4 cells with 2 μΜ 6MP induced cytotoxicity (Table 1) and led to int­
racellular depletion of purine nucleotides (Table 2). Depletion of guanine nucleotides 
occurred more rapidly than that of adenine nucleotides, but recovered earlier. Complete 
recovery of the guanine nucleotides could be observed after 48 hr. Maximal depletion of the 
adenine nucleotide pool occurred after 24 hr and lasted longer. Simultaneous addition of 
AICAR to treatment with 2 μΜ 6MP partly prevented cytotoxicity and resulted in a decre-
Table I. Cell number and cell viability of Molt F4 cells after 48 hr exposure to 2 μΜ 6MP, 0.5 μΜ 
MP A or a combination of both, and to 0.5 μΜ Me-MPR with or without addition of 50 μΜ AICAR. 
Cell number is expressed as IO1 viable cells/ml. Cell viability is expressed in %; mean ± SD of 
three independent experiments. ND: not done. 
control 
2 μΜ 6MP 
0.5 μΜ MPA 
2 μΜ 6MP + 0.5 
μΜΜΡΑ 
0.5 μΜ Me-MPR 
Cell number 
AICAR 
-
1.64 ± 0.15 
0.65 ± 0.25 
0.70 ± 0.1 
0.27 ± 0.09 
0.27 ± 0.06 
+ 
1.71 ± 0.24 
0.98 ± 0.15 
ND 
0.57 ± 0.06 
0.79 ± 0.12 
Cell viability 
AICAR 
-
97.5 ± 0 . 8 
78.0 ± 12.6 
75.7 ± 2.6 
47.4 ± 6.5 
60.6 ± 1.6 
+ 
97.4 ± 1.0 
90.9 ± 4.4 
ND 
68.0 ± 1.8 
91.0 ± 3.1 
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ased depletion of adenine nucleotides as compared to 6MP alone (Table 2). Depletion of 
guanine nucleotides could be partly prevented by AICAR during the first 2 hr. Decreased 
formation of tIMP and tGMP (results not shown) and of Me-tIMP (Fig. 1) was observed in 
cells treated with 6MP and AICAR as compared to 6MP alone. When 2 μΜ 6MP was com­
bined with 0.5 μΜ MPA, an inhibitor of the conversion of tIMP into thioguanine nucle­
otides under these conditions, more Me-tIMP was formed and cytotoxicity was potentiated 
(12). Addition of SO μΜ AICAR to this treatment resulted in cytotoxicity comparable to that 
of MPA alone (Table 1). 
Inhibition of purine de novo synthesis by Me-tIMP was examined further using Me-MPR as 
its precursor. Me-MPR (0.5 μΜ) induced inhibition of cell growth and cell viability (Table 
1) and resulted in depletion of purine nucleotides (Table 2). Addition of 50 μΜ AICAR to 
this treatment led to a complete recovery of cell viability and a partial recovery of cell 
growth (Table 1). Under these conditions adenine nucleotide concentrations partly recovered 
(Table 2), while guanine nucleotides recovered only during the first 6 hr of the treatment. 
Moreover, the intracellular formation of Me-tIMP was reduced as a result of treatment of 
cells with a combination of 0.5 μΜ Me-MPR and AICAR as compared to 0.5 μΜ Me-MPR 
alone, especially after prolonged incubation (Fig. 1). 
Me-tIMP (pmoles/10' іаЫе cells) 
1500 
1000 -
soo 
2μΜ 8MP 
2μΜ BMP 
+ AICAR 
I Ι 0.5μΜ M»-MPR 
I Ι 0.5μΜ M»-MPR 
+ AICAR 
48 72 
Time (h) 
Fig. 1. Me-tIMP concentration of Molt F4 cells treated with 2 μΜ 6MP or 0.5 μΜ Me-MPR alone, 
or in combination with 50 μΜ AICAR (expressed as pmoles/lff viable cells; mean with standard 
error of3 independent experiments). 
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Discussion 
In the present study the contribution of Me-tIMP formation to 6MP cytotoxicity is exa­
mined in Molt F4 cells. 6MP cytotoxicity is partly prevented by addition of AICAR to 6MP 
treatment (Table 1). Furthermore, AICAR ameliorates 6MP cytotoxicity in experiments 
where MPA is used to inhibit 6MP conversion into thioguanine nucleotides. 
Earlier research showed that with a combination of 2 μΜ 6MP and 0.5 μΜ MPA more Me-
tlMP is formed, and 6MP cytotoxicity is potentiated (12). Addition of AICAR to treatment 
with 0.5 μΜ MPA and 2 μΜ 6MP reduces cytotoxicity to a level obtained with MPA alone 
(Table 1). 
Prevention of 6MP cytotoxicity by AICAR may be attributed to two mechanisms. First, as a 
result of addition of AICAR the effects of inhibition of purine de novo synthesis by Me-
tlMP can be circumvented. This is demonstrated by the partial recovery of the adenine 
nucleotides (Table 2) after addition of AICAR. Second, Me-tIMP formation is decreased as 
a result of addition of AICAR to 6MP treatment (Fig. 1). This may be a consequence of 
phosphoribosylpyrophosphate consumption by the intracellular metabolism of AICAR (14) 
and may result in the availability of less phosphoribosylpyrophosphate for 6MP conversion 
into tIMP, and subsequently less intracellular thioguanine nucleotide formation. This com­
plicates elucidation of the effects of addition of AICAR on 6MP cytotoxicity. Therefore, 
combinations of Me-MPR and AICAR were used to investigate the effect of AICAR on 
inhibition of purine de novo synthesis by Me-tIMP more thoroughly, as Me-MPR is conver­
ted directly into Me-tIMP by the enzyme AK (11). This conversion is reflected by rapid 
formation of very high concentrations of Me-tIMP in the cells treated with 0.5 μΜ Me-
MPR (Fig. 2). The more severe depletion of adenine nucleotides as compared to guanine 
nucleotides by 0.5 μΜ Me-MPR (Table 2) could be ascribed both to consumption of ATP 
by AK, during conversion of Me-MPR into Me-tIMP, and to inhibition of adenine nucle­
otide formation as a consequence of competitive inhibition of AK by Me-MPR. Addition of 
AICAR restored cell viability and growth of cells treated with Me-MPR (Table 1). This is 
in accordance with data reported on amidoimidazolecarboxamide (AIC), which is also con­
verted into AICAR monophosphate and is able to reverse cytotoxicity of Me-MPR (15). 
Depletion of adenine nucleotides was partly prevented by addition of AICAR to Me-MPR 
treatment (Table 2). Simultaneously, a remarkable decrease in Me-tIMP concentration was 
observed (Fig. 1), probably as a result of competition for AK between AICAR and Me-
MPR. However, since 500 pmol Me-tIMP/10* viable cells induce complete inhibition of the 
purine de novo synthesis (16), the partial recovery of the adenine nucleotides observed here 
still is a result of circumvention of inhibition of purine de novo synthesis by AICAR, rather 
than of a suboptimal inhibition of purine de novo synthesis by a decreased Me-tIMP 
concentration. 
The partial recovery of adenine nucleotides by addition of AICAR (Table 2) was associated 
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with an almost complete recovery of cell viability and less inhibition of cell growth (Table 
1). Therefore, depletion of adenine nucleotides by Me-tIMP must be the main cause of Me-
tlMP cytotoxicity in Molt F4 cells. 
In conclusion, 6MP and Me-MPR cytotoxicity can be prevented by AICAR. These data 
confirm that formation of Me-tIMP may be a second important route for 6MP cytotoxicity. 
Whether the methylation route of tIMP is important for the therapeutic effects of 6MP in 
patients remains to be elucidated. The bioavailability of orally administered 6MP is low and 
under these conditions Me-tIMP formation may not be significant enough to inhibit purine 
de novo synthesis (12). Under these conditions the methylation route may even function as a 
detoxification pathway, as described by Lennard et al (17,18). However, when 6MP is 
administered intravenously very high levels are reached (19) and the methylation route may 
indeed contribute to 6MP cytotoxicity (12). 
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Reversal of methylmercaptopurine ribonucleoside cytotoxicity by 
intermediates of purine salvage pathway 
Summary 
Methyl-thioIMP (Me-tIMP), the sole metabolite of Me-MPR is a strong inhibitor of purine 
de novo synthesis, inducing depletion of intracellular purine nucleotides and subsequent cell 
death in several tumor cell lines. In this study prevention of methylmercaptopurine ribo­
nucleoside (Me-MPR) cytotoxicity by intermediates of the purine salvage pathway was stu­
died in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were 
able to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 
μΜ Me-MPR, but had virtually no effect on depletion of guanine nucleotides. Nevertheless, 
these three intermediates of purine salvage were able to ameliorate the cytotoxic effects 
induced by Me-MPR. Addition of guanosine to treatment with 0.5 μΜ Me-MPR repleted 
the guanine nucleotide pool, but adenine nucleotides remained depleted. Under these con­
ditions, inhibition of cell growth was slightly ameliorated. With a combination of guanosine 
and 10 μΜ Me-MPR cytotoxicity was increased as compared with 10 μΜ Me-MPR alone, 
associated with a depletion of adenine nucleotides to 9 % of untreated cells. Since cell 
growth and cell viability of Molt F4 cells are restored under conditions where adenine 
nucleotide depletion is reversed by intermediates of the purine salvage pathway and where 
the other nucleotides are depleted, we conclude that depletion of adenine nucleotides is an 
important factor for Me-MPR cytotoxicity. 
Introduction 
Methylmercaptopurine ribonucleoside (Me-MPR), a thiopurine antimetabolite, is cytotoxic 
for a number of cell lines and has some anticancer activity in vivo (1-5). Cytotoxicity of 
Me-MPR is mediated by its metabolite methyl-thioIMP (Me-tIMP), which is formed from 
Me-MPR by adenosine kinase (Scheme I) (3,6-8). Me-tIMP is a strong inhibitor of the pu­
rine de novo synthesis (9,10) at phosphoribosylpyrophosphate (PRPP) amidotransferase 
(9,11-13). Inhibition of this route induces a depletion of purine nucleotides (4,5,14-16), 
thereby leading to diminution of RNA and DNA formation (14) and subsequent inhibition of 
cell growth and loss of cell viability (3-5,15). 
Me-tIMP is also an important metabolite of the anticancer agent 6-mercaptopurine (6MP). 
6MP is first converted into thioIMP (tIMP) and the latter into Me-tIMP by thiopurine 
methyltransferase (17-19). 6MP is commonly used in the oral maintenance treatment of 
children with acute lymphoblastic leukemia (17,18). 
At present it is under discussion whether formation of Me-tIMP contributes to the anti-
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Scheme I. Purine salvage pathway 
Guanine 
nucleotides 
\ / 
XMP 
GMP 
4 І "4 
Guanosinel 2 
•Ι λ 
Guanine 
PRPP \ I 
Hypoxanthlne Adenine 
(1) Adenosine kinase (AK); (2) Hypoxanthine guanine phosphoribosyltransferase (HGPRT); 
(3) Adenine phosphoribosyltransferase (APRT); (4) 5' Nucleotidase (5'NT); (5) Purine nucleoside 
Phosphorylase (PNP); (6) Phosphoribosylpyrophosphate (PRPP) amidotransferase; 
(7) phosphoribosylpyrophosphate (PRPP) synthetase. 
cancer activity of orally administered 6MP (19). The metabolic route by which 6MP is ge­
nerally thought to induce cytotoxicity is conversion into 6-thioguanine nucleotides and 
subsequent incorporation into DNA and RNA (19,20). Furthermore, a high activity of thio-
purine methyltransferase in red blood cells, resulting in high Me-tIMP concentrations, is 
correlated with a poor prognosis in children receiving oral 6MP-therapy, suggesting that the 
methylation route of 6MP is a catabolic pathway (17,18). Our studies in Molt F4 cells, a 
human malignant lymphoblastic cell line, indicated that under conditions where intracellular 
Me-tIMP concentrations were elevated cytotoxicity of 6MP was increased (21). Cytotoxicity 
of both 6MP and Me-MPR could be reversed in these cells by addition of amidoimidazol-
ecarboxamide ribonucleoside, an intermediate of purine de novo synthesis distal to the Me-
tIMP inhibition site (22), further suggesting the cytotoxic potency of Me-tIMP in these 
cells. 
In the present study we obtained more evidence regarding cytotoxicity of Me-tIMP in Molt 
F4 human T-lymphoblasts. Cell growth, cell viability, endogenous nucleotide concentra-
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tions, extracellular nucleosides and bases and formation of Me-tIMP were determined in 
experiments where cells were treated with various concentrations of Me-MPR alone, or in 
combination with adenosine, adenine, inosine and guanosine, in order to determine whether 
cytotoxicity of Me-MPR could be prevented by purine intermediates of the purine salvage 
route (Scheme I). 
Materials and methods 
Me-MPR, adenosine, adenine, inosine and guanosine were obtained from Sigma Chemicals, 
USA. The experiments were performed with Molt F4 cells, a T-cell acute lymphoblastic 
leukemia cell line. Conditions for cell culture and experimental procedures have been 
described earlier (21). Me-MPR and adenosine, adenine, inosine, guanosine or combinations 
Me-MPR with one of these purine salvage intermediates were added as a single dose in a 
small volume (1/100). 
Intracellular nucleotides (di- and triphosphates) and Me-tIMP were extracted from 3 χ 10" 
viable cells by means of perchloric acid (PCA, BDH Chemicals Ltd, UK) extraction as 
previously described (21) and analyzed by means of HPLC at a wavelength of 254 nm (23). 
The concentrations were expressed as pmoles/10* viable cells. 
Extracellular nucleosides and bases were extracted from 0.5 ml of the medium, to which a 
volume of 25 μΐ 8 M PCA was added. This suspension was kept on ice for 10 min. Then 
the samples were centrifuged for 2 min., after which the supernatant was neutralized with 4 
M K2HP04. Nucleosides and bases were determined by means of reversed-phase HPLC, 
with a Supelcosil LC-18-DB column (25 cm χ 4.6 mm, Supelco, USA), and were detected 
at a wavelength of 254 nm. Concentrations were expressed as μιηοίεβ/ΐ. 
Results 
Treatment of Molt F4 cells with 0.5 μΜ Me-MPR resulted in decreased purine nucleotide 
concentrations (Table I) and led to inhibition of cell growth and of cell viability (Fig. 1). 
The effects of 10 μΜ Me-MPR on these parameters were similar (results not shown). 
Addition of 50 μΜ adenosine or adenine or 25 μΜ inosine to treatment with 0.5 μΜ Me-
MPR resulted in repletion of the intracellular adenine nucleotide pool within the first 24 h 
of the treatment (Table I). Adenosine was also able to restore the guanine nucleotide pool 
after 24 h. Adenine and inosine hardly affected the depletion of guanine nucleotides (Table 
I). These purine salvage intermediates were able to restore cell growth partially and cell 
viability nearly completely (Fig. 1). Combination of these purine salvage intermediates with 
10 μΜ Me-MPR led to similar results as with 0.5 μΜ Me-MPR, except for the reversal of 
depletion of guanine nucleotides by adenosine (results not shown). Addition of 25 μΜ 
guanosine to Me-MPR treatment resulted in an increase of intracellular guanine nuc­
leotides, but had little effect on the depletion of adenine nucleotides (Table I). Furthermore, 
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Fig. 1. Cell growth (a) and cell viability φ) of Molt F4 cells after treatment with 0.5 μΜ Me-MPR 
alone or in combination with 50 μΜ adenosine, 50 μΜ adenine or 25 μΜ inosine or 25 μΜ 
guanosine. The results of one experiment are shown. Similar results were obtained in two other 
experiments. 
this combination resulted in an almost complete recovery of cell viability (Fig. lb). Cell 
growth also partially restored (Fig. la). In contrast, guanosine in combination with 10 μΜ 
Me-MPR led to a large increase of cytotoxicity as compared to 10 μΜ Me-MPR alone. 
Under these conditions intracellular adenine nucleotides were depleted to 9 % of untreated 
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cells after 24 h (results not shown). 
To obtain insight in the metabolic fate of the purine intermediates after addition to the cells 
alone, or in combination with Me-MPR, concentrations of extracellular nucleosides and 
bases were determined. The results of these experiments are shown in tables II and III. 
Adenosine can be incorporated via 2 pathways; directly by adenosine kinase and indirectly 
by conversion into inosine, which is then converted into hypoxanthine and subsequently into 
IMP (Scheme I). This second route was reflected by the presence of extracellular ino-sine 
and hypoxanthine after addition of SO μΜ adenosine to Molt F4 cells (Table II). No 
extracellular adenosine was detected. When inosine is used as intermediate, inosine is first 
catabolized into hypoxanthine, which is subsequently converted by hypoxanthine-guanine 
phosphoribosyltransferase into IMP. Both inosine and hypoxanthine were detectable in the 
medium the first 6 h after the start of the experiment (Table II). Adenine is metabolized 
directly by adenine phosphoribosyltransferase into AMP and is present in the medium until 
48 h (Table III). After addition of guanosine alone, both guanosine and guanine are present 
(Table III). In general the disappearance of the purine salvage intermediates from the 
medium was slower when added in combination with 10 μΜ Me-MPR. 
Me-tIMP (pmoles/10e cells) 
2 6 24 48 72 
time (h) 
Fig. 2. Me-tIMP concentrations of Molt F4 cells treated with 0.5 μΜ Me-MPR alone or in combi­
nation with the purine salvage intermediates described in Fig. 1 (expressed as pmoles/lff viable 
cells; mean with standard error of3 independent experiments). 
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Me-tIMP concentrations were determined to evaluate the effects of the purine salvage 
intermediates on Me-MPR metabolism. Combination of 0.5 μΜ Me-MPR with the purine 
salvage intermediates resulted in a decrease of the Me-tIMP concentrations after 48 h (Fig. 
2). With 10 μΜ Me-MPR, addition of adenosine, adenine and inosine resulted in a decrease 
of Me-tIMP concentration. However, addition of guanosine led to a higher Me-tIMP con­
centration after 48 h as compared to 10 μΜ Me-MPR alone (5663 ± 482 and 4063 ± 351 
pmoles/10* viable cells, respectively). 
Discussion 
Me-MPR, an anticancer drug, exerts its cytotoxic activity by conversion into Me-tIMP, a 
strong inhibitor of the purine de novo synthesis (9,10). In this study the effects of Me-MPR 
on Molt F4 human T-lymphoblasts are determined. 
Inhibition of cell growth, cell viability and purine nucleotide concentrations (Fig. 1, Table 
I) is already maximal with 0.5 μΜ Me-MPR (24). With 10 μΜ Me-MPR no additional 
effects on cytotoxicity and on purine nucleotides are observed. Because Molt F4 cells have 
a highly active purine de novo synthesis (25), these cells are highly susceptible for Me-tIMP 
cytotoxicity. 
Adenosine, adenine and inosine are able to ameliorate Me-MPR-induced inhibition of purine 
de novo synthesis, leading to a partial restoration of cell growth and a nearly complete 
restoration of cell viability (Fig. 1, Table I). The effects of these three intermediates of 
purine salvage on purine nucleotide concentrations are comparable. The initial repletion 
during the first 24 h of intracellular adenine nucleotides is followed by depletion (Table I). 
This is the result of the very rapid conversion of the purine salvage intermediates, as de­
termined by the rapid disappearance of these intermediates and their dérivâtes from the 
incubation medium (Tables II and III). Reversal of the effects of 3 μΜ Me-MPR on induc­
tion of differentiation, cell growth inhibition and purine nucleotide concentrations by various 
concentrations of adenine was observed earlier in HL-60 cells (15) and in sarcoma 180 cells 
(26). 
With 10 μΜ Me-MPR restoration of the intracellular adenine nucleotide pool as a result of 
addition of the purine salvage intermediates is less pronounced (results not shown). This can 
be attributed to two phenomena. First, when adenosine is used in combination with a high 
concentration of Me-MPR, competition for adenosine kinase may occur, since both adenosi­
ne and Me-MPR are metabolized by this enzyme (Scheme I). As a result, less adenosine 
can be metabolized by the cells. This process is reflected by the prolonged presence of 
extracellular hypoxanthine (Table II), which is derived from adenosine catabolism and 
which indicates a slow anabolism of adenosine under these conditions. Second, it is known 
from the literature (27,28) and from our earlier research (24) that a high Me-tIMP concen-
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tration results in inhibition of PRPP synthetase. As PRPP is a cofactor for the enzymes 
adenine phosphoribosyltransferase and hypoxanthine guanine phosphoribosyltransferase and 
thus is involved in the metabolism of adenine and inosine (the latter being first converted 
into hypoxanthine), less adenine and inosine will be incorporated into the cells with 10 μΜ 
Me-MPR. Again, this is reflected by the concentrations of extracellular adenine and hypo­
xanthine after treatment with 10 μΜ Me-MPR in combination with either inosine (Table Π) 
or adenine (Table III). 
The minor effects of adenine, adenosine and inosine on the intracellular guanine nucleotide 
depletion (Table I) are probably the result of the importance of the adenine-guanine nuc­
leotide balance, which results in the selective restoration of the adenine nucleotide concen­
tration. Moreover, interconversion into guanine nucleotides is a much slower process than 
interconversion into adenine nucleotides (29). 
The severe cytotoxicity observed with the combination of 10 μΜ Me-MPR and 25 μΜ 
guanosine can be ascribed to a nearly complete depletion of the intracellular adenine 
nucleotides, which is induced by several mechanisms. First, inhibition of the purine de novo 
synthesis by Me-MPR will result in a depletion of the adenine nucleotides. Second, Me-
MPR is converted into Me-tIMP by the enzyme adenosine kinase, a reaction which consu­
mes ATP and thus induces a further decrease of adenine nucleotide concentrations. Third, 
addition of guanosine leads to an increase of guanine nucleotides of 2.5 times the control 
value at 48 h (results not shown). The formation of GDP and GTP from GMP consumes 
ATP by kinase reactions. Therefore the adenine nucleotide pool will be depleted further, 
leading to the dramatic reduction of intracellular adenine nucleotides observed in these 
experiments. Combination of guanosine with 0.5 μΜ Me-MPR does not induce such a 
severe depletion of the adenine nucleotides (Table I), since at this concentration of Me-MPR 
less ATP is consumed as a consequence of the adenosine kinase-mediated conversion of Me-
MPR into Me-tIMP. Exacerbation of cytotoxicity of Me-MPR by guanosine was reported 
earlier (15,30,31) and was explained by these authors by a synergistic action between GMP 
and Me-tIMP, resulting in a more severe inhibition of purine de novo synthesis, presumably 
at PRPP amidotransferase (30). The results from our study do not confirm this conclusion, 
since the guanine nucleotide pools are also elevated with the combination of 0.5 μΜ Me-
MPR and guanosine, which does not lead to a more severe depletion of adenine nucleotides 
as compared to 0.5 μΜ Me-MPR alone (Table I). The more severe inhibition of the purine 
de novo synthesis with the combination of 10 μΜ Me-MPR and guanosine rather is the re­
sult of the severe depletion of the adenine nucleotide pool, observed under these conditions. 
For one, the conversion of ribose-5 '-phosphate to PRPP is ATP dependent, so severe deple­
tion of ATP may lead to less availability of PRPP for purine de novo synthesis (24). 
The decrease of Me-tIMP concentrations as a result of addition of adenosine as compared to 
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treatment with Me-MPR alone (Fig. 2) may be the result of competition between adenosine 
and Me-MPR for adenosine kinase, since both compounds are metabolized by this enzyme. 
It is at present not clear how addition of adenine, inosine and guanosine affects Me-tIMP 
formation. 
In conclusion, depletion of the intracellular adenine nucleotide concentration appears an 
important factor for Me-MPR cytotoxicity. This is in contrast with earlier observations that 
the biological consequences of purine starvation as a result of Me-MPR treatment were pri­
marily a consequence of guanine nucleotide depletion in a mouse T-lymphoma cell line 
(14). As a result of addition of adenosine, adenine and inosine to treatment with Me-MPR, 
the adenine nucleotides restored to control values within the first 24 h of the treatment 
(Table I), whereas guanine nucleotides remained depleted (Table I) and pyrimidine nucle­
otides (data not shown) became depleted as a result of higher consumption of PRPP by the 
purine salvage intermediates. Since under these conditions cell growth and cell viability of 
Molt F4 cells still partly recovered to control values, restoration of the depletion of adenine 
nucleotides is also important for amelioration of the effects of inhibition of purine de novo 
synthesis by Me-MPR. Furthermore, it appears of importance to use at least two concentra­
tions of Me-MPR in stu-dying the effects of purine salvage intermediates on Me-MPR 
induced cytotoxicity, since this reveals more of the underlying mechanisms of cytotoxicity. 
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Reduction of S-adenosylmethionine synthesis by 6-mercaptopurine and 
methylmercaptopurine ribonucleoside in Molt F4 human malignant 
lymphoblasts 
Summary 
6-Mercaptopurine (6MP) and methylmercaptopurine ribonucleoside (Me-MPR) are purine 
antimetabolites which are both metabolized into Me-tIMP, a strong inhibitor of the purine 
de novo synthesis. Me-MPR is converted directly into Me-tIMP by adenosine kinase. 6MP 
is converted into thio-IMP (tIMP) and thereafter it is methylated into Me-tIMP by thio-
purine methyltransferase, a S-adenosylmethionine (AdoMet) dependent conversion. AdoMet 
is formed out of methionine and ATP by methionine adenosyltransferase and is a universal 
methyldonor, involved in methylation of several macromolecules, e.g. DNA and RNA. 
Therefore, depletion of AdoMet could result in altered methylation state of these macromo-
lecules, thereby affecting their functionality, leading to dysregulation of cellular processes 
and cytotoxicity. In this study the effects of 6MP and Me-MPR on AdoMet, S-adenosyl-
homocysteine (AdoHcy), homocysteine and methionine concentrations are determined. Both 
drugs cause a decrease of intracellular AdoMet concentrations and an increase of AdoHcy 
and methionine concentrations in Molt F4 human malignant lymphoblasts. The effects of 
both 6MP and Me-MPR can be ascribed to a reduced conversion of methionine into 
AdoMet, due to the ATP depletion induced by Me-tIMP formation. The observed decrease 
of the AdoMet/AdoHcy ratio by 6MP and Me-MPR affects the methylation state of the 
cells. This may result in dysregulation of cellular processes and may be an additional 
mechanism of cytotoxicity for 6MP and Me-MPR. 
Introduction 
6-Mercaptopurine (6MP), an analogue of the purine base hypoxanthine, is commonly used 
in the maintenance treatment of children with acute lymphoblastic leukemia (1). Two 
metabolic pathways contribute to 6MP cytotoxicity (Scheme 1). Both pathways are initiated 
by the conversion of 6MP into thio-IMP (tIMP) by the purine salvage enzyme hypoxanthine 
guanine phosphoribosyltransferase (2,3). Subsequently, tIMP can either be incorporated into 
DNA as thioguanine nucleotides (4-6), resulting in DNA damage (7-10) and consequently to 
delayed cytotoxicity (4,11,12), or ÜMP can be methylated into methyl-tIMP (Me-tIMP). 
Me-tIMP is a strong inhibitor of purine de novo synthesis (13-15), inducing depletion of 
purine nucleotides. As a consequence, DNA and RNA synthesis become inhibited, resulting 
also in inhibition of cell growth and cytotoxicity (16,17). 
Methylmercaptopurine ribonucleoside (Me-MPR), an other purine antimetabolite, exerts its 
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Scheme 1. 6-mercaptopurine metabolism and transmethylation pathway 
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cytotoxicity only after its conversion into Me-tIMP (16-19). Me-MPR is metabolized direct-
ly into Me-tIMP by adenosine kinase, in an ATP-dependent reaction (15,19-21). 
Methylation of tIMP into Me-tIMP is a S-adenosylmethionine (AdoMet) dependent con-
version, catalyzed by thiopurine methyltransferase (TPMT) (22-26). AdoMet serves as 
methyl donor for numerous methyltransferases, including those involved in methylation of 
proteins, phospholipids and nucleic acids, thereby affecting their function (27). These 
methyltransferases convert AdoMet into S-adenosylhomocysteine (AdoHcy), which is fur-
ther converted into adenosine and homocysteine by AdoHcy hydrolase (28) (Scheme 1). 
Regeneration of AdoMet occurs by re-methylation of homocysteine into methionine by the 
vitamin B12 and methylenetetrahydrofolate reductase dependent methionine synthase. 
Methionine is the direct precursor for AdoMet synthesis (29,30). Alterations in the 
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transmethylation pathway have been found in most tumor cell lines and methionine-
dependency is often observed in malignant cell lines (31). 
In the present study the effects of various concentrations of 6MP and Me-MPR on cell 
growth, cell viability and ATP concentrations were determined in Molt F4 human malig­
nant lymphoblasts. Because the conversion of 6MP into Me-tIMP consumes AdoMet, the 
concentrations of AdoMet, AdoHcy, homocysteine, methionine and of Me-tIMP were deter­
mined to establish possible effects of 6MP on the transmethylation pathway. The effects of 
Me-MPR on these parameters were also determined because Me-MPR is also converted into 
Me-tIMP, however, without the consumption of AdoMet. 
Materials and Methods 
Chemicals. 
6MP, Me-MPR, S-adenosyl-L-methionine and S-adenosyl-homocysteine were obtained from 
Sigma Chemicals, USA. 
Cells. 
The experiments were performed with Molt F4 cells, a human T-cell acute lymphoblastic 
leukemia cell line. Conditions for cell culture have been previously described (32). 
Experimental procedures. 
Twentyfour h prior to the start of the experiments, logarithmically growing cells were 
seeded in a concentration of 0.2 χ 10* cells per ml. At t = 0 6MP or Me-MPR were added 
as a single dose in a small volume (1/100). During the experiments 2 mM glutamine was 
supplemented every 24 h in order to prevent glutamine exhaustion of the medium (33). 
After incubation, the cells were harvested and counted with a coulter counter. Cell viability 
was determined by means of trypan blue exclusion. Cell growth was determined by 
counting the cells and correcting cell number for cell viability. 
Determination of endogenous nucleotides and thionucleotides. 
Endogenous nucleotides (di- and triphosphates) were determined in 3 χ 10e viable cells, 
according to the method described before (34), and were measured at a wavelength of 
254 nm. Nucleotide concentrations were expressed as pmoles/104 viable cells. Thionucleo­
tides were extracted from 107 viable cells, according to the procedure described earlier (32). 
Thio-GMP was determined at 320 nm. Me-tIMP was measured at 290 nm. Concentrations 
were expressed as pmoles/10* viable cells. 
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Determination of AdoMet and AdoHcy. 
AdoMet and AdoHcy concentrations were determined by means of HPLC in 107 viable cells 
according to the method described by Molloy et al. (35). The cell pellet was resuspended in 
200 μ\ of 25 mM potassium phosphate buffer, pH 6.0 and proteins were precipitated by 
add-ing 20 /tl 50 % trichloroacetic acid (TCA, BDH Chemicals Ltd, UK). The samples 
were kept on ice for 10 minutes and then centrifugea at 13,000 g for 2 minutes. Superna-
tants were collected and washed 3 times with 2 volumes of peroxide-free diethylether to 
remove TCA. The samples were flushed with nitrogen, while being on ice, and diluted with 
aquadest to an end volume of 200 μΐ. Hereafter, AdoMet and AdoHcy were separated on a 
Waters μBondapak C18 column (3.9 χ 30 mm). Separation was performed with a gradient 
consisting of two buffers. Buffer A consisted of 25 mM potassiumphosphate (Sigma Chem­
icals, USA) and 10 mM heptansulphonic acid (Sigma Chemicals, USA), pH 3.2. Buffer В 
consisted of 12.5 mM potassiumphosphate, 50 % methanol and 10 mM heptansulphonic 
acid. The gradient was built up during consecutive time-points as follows: start 70 % buffer 
A + 30 % buffer B, 11 minutes 40 % A + 60 % B, 19 minutes 20 % A + 80 % B, 21 
minutes 70 % A + 30 % B. One run lasted 30 minutes. The samples were analyzed by 
means of HPLC, consisting of a Kontron autosampler (MS1660, The Netherlands), a 
Spectra Physics pump (SP8800, Santa Clara, CA) and a uv spectrophotometer from ABI 
Separations (759A, The Netherlands). The data were processed with Spectra Physics 
Winner software (Santa Clara, CA). 
Determination of extracellular homocysteine. 
Total homocysteine concentrations were determined in 1 ml of culture medium after treat­
ment of the cells with 6MP or Me-MPR. Samples were lyophilized overnight and thereafter 
resuspended in 0.2 ml aquadest. Subsequently total homocysteine was determined by means 
of HPLC, essentially according to the method described by Fiskerstrand et al. (36). A 
programmable sample processor (Gilson, model 232 BIO, Dilutor 401) was used for the 
automated homocysteine derivatization and sample injection. The pump (SP8800), the inte­
grator (SP4400) and the fluorescence spectrophotometer (Linear Fluor LC 304) were from 
Spectra Physics (Santa Clara, CA). 
Determination of intracellular methionine. 
The intracellular methionine concentration was determined in 5 χ 10* viable cells. The cells 
were centrifuged (5 minutes, 800 g) and the cell pellet was resuspended in 0.2 ml aquadest. 
The cells were sonified (3x10 sec, 15 Watt, Branson sonifier) and proteins were precipitat­
ed with 0.1 ml 18.8 % sulphosalicylic acid (Merck, Germany) with norleucine (600 /imol/1, 
Merck, Germany) as an internal standard. The suspension was kept on ice for 10 minutes. 
Subsequently, 0.1 ml buffer (pH 3.4) consisting of 0.2 M lithium citrate, 50 mM citric acid 
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(Merck, Germany), 200 mM lithium hydroxide (Fluka Chemie AG., Switz-erland), 10 mM 
phenol, 0.2 % thiodiglycol and 0.06 % HCl (Merck, Germany) was added and the 
suspension was centrifuged (4 minutes, 12,000 g). 0.2 ml aquadest were added to 0.2 ml of 
this suspension and 0.2S ml were used for determination of methionine. Methionine 
concentrations were determined using ion-exchange chromatography on an ami-noacid 
analyzer (Biotronik LC6001) according to the procedure from the manufacturer, with some 
modifications. To increase sensitivity of the method the aminoacids were derivatized with 
ortho-phtaldialdehyde (OPA, Sigma Chemicals, USA) and the methionine-ortho-phtal-
dialdehyde adduct was quantified with a fluorescence detector (Jasco, model 821-FP). 
Results 
6MP induced a concentration dependent cytotoxicity in Molt F4 cells (results not shown). 
Me-tIMP was detected in cells treated with 6MP (Table I). With 10 μΜ 6MP more Me-
tlMP was formed than with 2 μΜ and with 10 μΜ 6MP the Me-tIMP concentration still 
increased after 24 h (Table I). The ATP concentration decreased as a result of treatment 
with 6MP (Table I). 10 μΜ 6MP induced a more severe depletion of ATP as compared to 2 
μΜ 6MP. 6MP also decreased the concentration of AdoMet (Table II). Furthermore, 
treatment with 5 μΜ and 10 μΜ 6MP resulted in an increase of the AdoHcy concentration. 
The decrease of AdoMet and increase of AdoHcy resulted in a concentration-dependent 
decrease of the AdoMet/AdoHcy ratio. 
After treatment with 6MP excretion of homocysteine was lower as compared to untreated 
cells (Table II). This was especially obvious 48 h after treatment. The intracellular 
homocysteine concentration in Molt F4 cells was below the detection limit. Intracellular met­
hionine concentrations increased after treatment with 6MP (Table II). With 2 μΜ 6MP some 
restoration of methionine concentration appeared after 48 h. With 5 μΜ and 10 μΜ 6MP 
Table I 
ATP and Me-tIMP concentrations in Molt F4 cells treated with 2 or 10 μΜ 6MP. ATP concentration 
is expressed as pmol/lO' viable cells; median and range (between brackets) of 9 independent 
experiments. Me-tIMP concentrations are expressed in pmoles/W viable cells; median and range 
(between brackets) of 8 independent experiments. 
time (h) 
24 
48 
ATP 
Control 2 μΜ 6MP 10 μΜ 6MP 
5481(3191-5792) 2516(1886-3136) 1553(963-2201) 
4056(2213-4532) 3084(2118-3671) 2023(1365-2533) 
Me-tIMP 
2 μΜ 6MP 10 μΜ 6MP 
119 (65-268) 338 (276-545) 
77 (25-301) 799 (291-868) 
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the methionine concentration increased further between 24 and 48 h. 
The AdoMet/AdoHcy ratio appeared correlated with the ATP concentration, whereas the 
concentration of intracellular methionine appeared inversely correlated with ATP (Fig. 1). 
Me-MPR is also converted into Me-tIMP, resulting in inhibition of purine de novo syn­
thesis and ATP depletion. However, for this conversion no AdoMet is required. Therefore, 
the effects of Me-MPR on the inter-mediates of the methylation pathway were also deter­
mined. Me-MPR was also cytotoxic for Molt F4 cells, with maximal cytotoxicity at 0.5 μΜ 
Me-MPR (see chapter 5). Very high concentrations of Me-tIMP accumulated in cells treated 
with Me-MPR (Table ΙΠ). After treatment with 0.2 μΜ Me-MPR the Me-tIMP concentra­
tion resembled that of cells, treated with 10 μΜ 6MP (Tables I and III). 0.2 μΜ Me-MPR 
resulted already in maximal inhibition of purine de novo synthesis during the first 24 h, as 
indicated by the depletion of the ATP pool (Table III). After 48 h, some restoration of the 
ATP pool occurred, especially in cells treated with 0.2 μΜ Me-MPR. 
Me-MPR also induced a decrease of the AdoMet concentration and an increase of AdoHcy, 
resulting in a decreased AdoMet/AdoHcy ratio (Table II). Again, extracellular homocysteine 
6MP concentration (μΜ) 
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Fig. 1. Correlation between ATP concentration and methionine concentration and the AdoMet/Ado­
Hcy ratio after treatment with 6MP for 24 h. The results of 1 experiment are shown. Similar results 
were obtained in 2 other experiments. 
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diminished as a result of treatment with Me-MPR as compared to untreated cells (Table Π). 
This effect became obvious after 24 h and was more pronounced than after 6MP treatment. 
The methionine concentration also increased as a result of treatment with Me-MPR 
(Tablell). The effects of Me-MPR on AdoMet, AdoHcy, methionine and homocysteine were 
comparable to those of 6MP. 
Discussion 
Extensive research has been performed to elucidate the mechanisms by which 6MP exerts 
its cytotoxic effects on tumor cells. Most attention has been focused on incorporation of 
6MP into DNA as thioguanine nucleotides (4-6,11,12), whereas the methylation pathway for 
6MP metabolism was considered to be a detoxifying process after low dose oral mainte­
nance treatment and therefore negatively affecting therapy (37-39). However, our earlier 
studies indicated that the methylation route of 6MP, using concentrations of 2 μΜ and 10 
μΜ 6MP, contributed to cytotoxicity by induction of inhibition of purine de novo syn-thesis 
(17,32,40). We now postulate a new mechanism by which formation of Me-tIMP from 6MP 
may also disturb various cellular processes, thereby inducing additional cytotoxicity. 
Treatment of Molt F4 human malignant lymphoblasts with 6MP results in a depletion of 
AdoMet and an increase of AdoHcy, leading to a concentration-dependent decrease of the 
AdoMet/AdoHcy ratio (Table II). Theoretically, the depletion of AdoMet can be ascribed to 
two mechanisms. First, the 6MP metabolite tIMP is methylated by thiopurine methyl-trans-
ferase with AdoMet as methyldonor, thereby consuming AdoMet. However, with 2 μΜ 
6MP less Me-tIMP is formed as compared with 10 μΜ 6MP (Table I), whereas AdoMet is 
equally depleted at these two concentrations of 6MP (Table IT). Second, as a result of 6MP 
treatment and subsequent Me-tIMP formation, the purine de novo synthesis is inhibited, 
resulting in a depletion of ATP (Table I). ATP is also required as a substrate in the 
formation of AdoMet from methionine by methionine adenosyltransferase (Scheme 1). So 
depletion of ATP hampers the conversion of methionine into AdoMet. This mechanism 
could also account for the observed decrease of AdoMet and would explain the increase of 
the methionine concentrations (Table Π). 
To discriminate between both mechanisms we studied the effects of Me-MPR. Since Me-
MPR is converted directly into Me-tIMP by adenosine kinase, no consumption of AdoMet 
occurs, whereas inhibition of purine de novo synthesis does occur. Furthermore, conversion 
of Me-MPR into Me-tIMP by adenosine kinase consumes ATP, and Me-MPR competitively 
inhibits adenosine kinase (chapter 6). Both mechanisms also contribute to the ATP depletion 
that results from Me-MPR treatment. In this way we could discriminate between the effects 
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of AdoMet consumption by methylation of tIMP into Me-tIMP versus reduced AdoMet syn­
thesis as a result of ATP depletion. Overall, the effects of Me-MPR closely resemble those 
of 6MP. This demonstrates that the decreased AdoMet concentrations are caused by reduced 
synthesis due to decreased ATP levels. 
The observed increase of the AdoHcy concentration (Table ΠΓ) can not be explained by 
reduced synthesis of AdoMet. Conversion of AdoHcy into homocysteine by AdoHcy hydro­
lase is a reversible reaction, with its equilibrium strongly in favour of AdoHcy formation 
and an excess of adenosine induces accumulation of AdoHcy (28). Since Me-MPR is an 
analogue of adenosine, administration of Me-MPR could lead to the same effect, thereby in­
ducing accumulation of AdoHcy and decrease of formation and excretion of homocysteine. 
This mechanism could also account for the effects of 6MP, since Me-MPR is also a 
metabolite of 6MP. 
The observed effects of 6MP and Me-MPR on the transmethylation pathway may contribute 
to knowledge of 6MP cytotoxicity. First of all, AdoMet is the methyl donor for numerous 
methyltransferases, and is involved in methylation of e.g. nucleic acids, proteins and 
phospholipids (27), while AdoHcy is a potent inhibitor of most AdoMet-dependent trans-
methylases (28,41). So, the AdoMet/AdoHcy ratio is a major determinant of the cellular 
transmethylase activity (42). Compounds which influence pool sizes of AdoMet and 
AdoHcy and therefore the ratio of AdoMet/AdoHcy, may directly influence cellular 
methylation reactions, for instance methylation of DNA (31,43). This may induce diffe­
rentiation in several tumor cell lines (44,45). Furthermore, methylation of DNA is thought 
to play a major role in gene regulation (46) and aberrant methylation patterns exist in DNA 
of tumor cells (31,47-49). Therefore, tumor cells may be especially sensitive to depletion of 
AdoMet. 
In conclusion, both 6MP and Me-MPR may function as inhibitors of intracellular transme­
thylation reactions, due to a reduced AdoMet formation, thereby affecting cellular mecha­
nisms on many different levels. Therefore, further research is warranted, possibly leading to 
a better understanding of the importance of the methylation route for 6MP cytotoxicity. 
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Summary 
6MP was introduced as a drug against acute lymphoblastic leukemia some 40 years ago (1) 
and ever since, much research on its mechanisms of action has been performed. 6MP is 
metabolized by two pathways. The first one is conversion into thioguanine nucleotides and 
subsequent incorporation into RNA and DNA, thereby inducing DNA damage and leading 
to delayed cytotoxicity (2-17). The second one is formation of Me-tIMP and subsequent 
inhibition of purine de novo synthesis (PDNS). Inhibition of the PDNS leads to a depletion 
of purine nucleotide concentrations and results in inhibition of DNA synthesis (13,15,17-
34). This leads to inhibition of cell growth and after prolonged exposure or exposure to 
high concentrations, to cell death. Adenine nucleotides function as energy donors for 
numerous metabolic processes (35) and guanine nucleotides are involved in processes such 
as protein synthesis, polyamine synthesis, microtubule assembly and intracellular signal 
transduction (36,37,38). So, depletion of purine nucleotides may induce cytotoxicity by 
many different mechanisms. 
Incorporation of 6MP into DNA as thioguanine nucleotides is considered to be the main 
mechanism for 6MP cytotoxicity (3,5,7,12-15). In contrast, formation of Me-tIMP is consi-
dered to prevent cytotoxicity, since studies in leukemia patients receiving low dose oral 
6MP reveal that an active thiopurine methylation pathway in red blood cells correlates with 
a poor prognosis (39). Furthermore, in patients with low or absent thiopurine methyltrans-
ferase (TPMT) activity, high concentrations of thioguanine nucleotides are detected in red 
blood cells and at the same time these patients are at risk for severe cytotoxic side-effects of 
the treatment (40,41). Other studies, however, indicate a role for Me-tIMP in 6MP 
cytotoxicity, since in phytohemaglutinin stimulated peripheral blood lymphocytes of subjects 
with genetically low TPMT activity, more 6MP is required for a 50 % inhibition of DNA 
synthesis, indicating that Me-tIMP may be of importance for 6MP cytotoxicity (42). 
Furthermore, Me-MPR, from which Me-tIMP is the sole active metabolite, has been used 
as an anticancer drug with pronounced cytotoxicity (27,28,43-47). These observations 
indicate the potential importance of Me-tIMP for 6MP and Me-MPR cytotoxicity. 
The aim of this study was to obtain more knowledge on the importance of methylation for 
6MP cytotoxicity. In previous years, investigators from our laboratory have extensively 
studied 6MP metabolism in vitro (16,17,48) and its pharmacokinetics in patients receiving 
oral 6MP treatment, as well as in dogs, goats and monkeys (32,49). Sensitive HPLC met-
hods have been developed to determine both endogenous nucleotides and thiopurine nucle-
otides (50-52). These methods have provided us with the tools to study 6MP metabolism in 
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more detail in in vitro cell culture. 
The experiments are performed in Molt F4, a T-cell ALL cell line. This is especially im­
portant, since leukemia cells are the ultimate target of the therapy and drug effects should 
be evaluated in cells closely resembling the target cells. 
Chapter 1 reviews the knowledge concerning the mechanisms of 6MP cytotoxicity at the 
start of this study. 
In chapter 2 the development of a sensitive micro-assay for measurement of the activity of 
IMPDH, the rate-limiting enzyme in purine interconversion and its inhibition by mycophe-
nolic acid (MPA) are described. The specific activity of IMPDH in Molt F4 cells appears to 
be nearly twice as high as that in another leukemic cell line, KM3, which is a non-B,non-T 
common ALL cell line. This indicates a high activity of purine metabolism in Molt F4 
cells. MPA indeed inhibits the activity of IMPDH, as determined in pre-incubation experi­
ments. This enables us to use MPA to study the importance of Me-tIMP formation for 6MP 
cytotoxicity in more detail, by preventing the conversion of tIMP into thioguanine nucleoti­
des. 
To determine the in vitro effects of MPA on cell growth and cell viability, Molt F4 cells 
are treated with several concentrations of MPA (chapter 3). MPA appears to be cytotoxic 
for Molt F4 cells. Cytotoxicity is concentration dependent. Furthermore, MPA induces a 
depletion of the guanine nucleotide concentration when administered to cells. Both cyto­
toxicity and depletion of intracellular guanine nucleotides is prevented by addition of 
guanosine to cells treated with MPA. Daily additions of guanosine are required to prevent 
cytotoxicity during the entire incubation period. In line with the high activity of purine 
salvage pathway and nucleotide metabolism, the intracellular guanine nucleotide concentra­
tions rapidly decrease after an initial increase, when guanosine is added to the cells treated 
with MPA. 
To study the importance of Me-tIMP formation for 6MP cytotoxicity more specifically, ef­
fects of combination of 6MP and MPA on cell viability and cell growth are studied (chapter 
4). Based on the severe cytotoxicity of MPA (chapter 3), it is necessary to use low concen­
trations of MPA in the experiments where MPA is combined with 6MP. 
The first indication for the importance of Me-tIMP for 6MP cytotoxicity is the observed 
synergism between 2 μΜ 6MP and 0.5 μΜ MPA. Since IMPDH is involved in the conver­
sion of tIMP into thioguanine nucleotides, inhibition of this enzyme by MPA will decrease 
the formation of thioguanine nucleotides, leading to inhibition of incorporation of thio­
guanine nucleotides into RNA and DNA. Indeed, during the first 24 h after MPA and 6MP 
administration less tGMP was measured as compared to 6MP alone. Furthermore, the form­
ation of Me-tIMP was increased after combination of 0.5 μΜ MPA and 2 μΜ 6MP. The 
observation that both cytotoxicity and Me-tIMP concentration increased as a result of 
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addition of MPA to 6MP treatment led to the conclusion that formation of Me-tIMP indeed 
may be of importance for the cytotoxicity of 6MP in lymphoblastic cells with an active 
PDNS. 
Concentration dependent inhibition of PDNS by Me-tIMP is studied with increasing concen­
trations of Me-MPR (Chapter 5). Even as little as 0.1 μΜ Me-MPR results in maximal in­
hibition of PDNS, as reflected by the depletion of the purine nucleotides and by the increase 
of phosphoribosyl pyrophosphate (PRPP). The concentration of Me-tIMP which induces a 
maximal PRPP concentration and produces maximal effects on PDNS is 500 pmoles/lO* 
viable cells. This concentration is also obtained in cells, treated with 10 μΜ 6MP, or with 
the combination of 2 μΜ 6MP and 0.S μΜ MPA (chapter 4), indicating again that under 
these conditions inhibition of PDNS may indeed have a part in 6MP cytotoxicity. 
The effects of inhibition of PDNS by Me-tIMP are examined in more detail by simultaneous 
prevention of purine nucleotide depletion. If Me-tIMP formation indeed exerts such a 
crucial effect, this should be eliminated by prevention of depletion of purine nucleotides, 
thereby decreasing 6MP cytotoxicity. Depletion of purine nucleotides can be prevented in 
two ways. First, by addition of AICAR, an intermediate of PDNS distal to the site of inhi­
bition by Me-tIMP (Chapter 6). Second, by addition of intermediates of purine salvage, 
such as adenine, adenosine, inosine and guanosine (Chapter 7). 
Addition of SO μΜ AICAR to treatment with 2 μΜ 6MP indeed results in prevention of 
depletion of especially adenine nucleotides and a subsequent decrease of cytotoxicity (Chap­
ter 6). However, as a result of addition of AICAR the concentrations of the intracellular 
metabolites of 6MP, being Me-tIMP, tIMP and tGMP, also decrease. Intracellular conver­
sion of AICAR consumes PRPP. Since PRPP is also a cofactor for the conversion of 6MP 
into tIMP, addition of AICAR may diminish the incorporation of 6MP into the cells. 
Furthermore, cytotoxicity induced by 6MP partly results from incorporation of thioguanine 
nucleotides into DNA. So, the decrease of cytotoxicity after addition of AICAR can not 
exclusively be ascribed to prevention of depletion of purine nucleotides by circumventing 
the inhibition of PDNS. 
Me-MPR is a thiopurine antimetabolite which sole metabolite is Me-tIMP. Therefore, by 
repeating the experiments with Me-MPR, instead of 6MP, the cytotoxic effects caused by 
inhibition of PDNS by Me-tIMP can be studied exclusively. Combination of Me-MPR and 
AICAR also results in decreased cytotoxicity, and restoration of purine, especially adenine 
nucleotide pools. Therefore these experiments stress the importance of Me-tIMP formation 
for cytotoxicity in Molt F4 cells. Furthermore, addition of AICAR hardly affects depletion 
of guanine nucleotide concentrations, but predominantly restores the adenine nucleotide 
concentrations, which indicates that depletion of adenine nucleotides, rather than of guanine 
nucleotides, is important for cytotoxicity of both drugs. Again, these experiments attribute 
to the idea that formation of Me-tIMP may induce cytotoxicity, especially in cells which 
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have a highly active PDNS. 
This becomes also obvious from experiments where the intermediates of purine salvage ade­
nosine, adenine, inosine and guanosine are used to prevent purine nucleotide depletion 
(Chapter 7). Adenosine, adenine and inosine are able to prevent depletion of adenine nucle­
otides, but not of guanine nucleotides in cells treated with 0.5 μΜ Me-MPR. At the same 
time combination of each of these purine salvage intermediates with 0.5 μΜ Me-MPR 
reduces cytotoxicity, thereby indicating that depletion of adenine nucleotides is the pre­
dominant cause of Me-tIMP induced cytotoxicity. 
Addition of guanosine to treatment with 0.5 μΜ Me-MPR results in repletion of guanine 
nucleotides, associated with a more severe depletion of adenine nucleotides, especially early 
after addition of guanosine to treatment with 0.5 μΜ Me-MPR. At the same time, combina­
tion of 0.5 μΜ Me-MPR with guanosine also results in decreased cytotoxicity, indicating 
that depletion of guanine nucleotides also contributes to Me-tIMP cytotoxicity. Combination 
of guanosine with 10 μΜ Me-MPR results in a nearly complete depletion of adenine nucle­
otides, and an increase of cytotoxicity over that of 10 μΜ Me-MPR alone. The fact that 
depletion of ATP is so complete with the combination of a high concentration Me-MPR 
with guanosine can be ascribed to three processes. First, inhibition of PDNS by Me-MPR. 
Second, competitive inhibition of adenosine kinase by Me-MPR with respect to adenosine, 
and consumption of ATP during conversion of Me-MPR into Me-tIMP. Third, consumption 
of ATP by the conversion of guanosine into GTP, which concentration becomes extremely 
high upon addition of guanosine to the cells. 
Thiopurines are methylated by thiopurine methyltransferase, with S-adenosylmethionine 
(AdoMet) as methyl-donor. As a result S-adenosylhomocysteine (AdoHcy) is formed. 
AdoMet is also the methyldonor for many other intracellular molecules, thereby regulating 
their functionality. Therefore, drugs which influence the intracellular methylation capacity 
may influence cellular processes on many levels. In chapter 8 the effects of treatment with 
either 6MP or Me-MPR on intermediates of the remethylation pathway, AdoMet, AdoHcy, 
homocysteine and methionine are examined. Me-MPR is converted directly into Me-tIMP 
by adenosine kinase with ATP as a co-substrate. This conversion is AdoMet independent, in 
contrast to Me-tIMP formation from 6MP. However, both 6MP and Me-MPR depleted the 
methylation capacity of the treated cells, reflected by a decreased AdoMet/AdoHcy ratio, as 
a result of a decrease of the AdoMet concentration and increase of AdoHcy. The decrease 
of AdoMet by 6MP can be ascribed to two mechanisms. First AdoMet is consumed for 
methylation of tIMP by thiopurine methyltransferase. Second, AdoMet formation appears to 
be inhibited as a consequence of ATP depletion resulting from inhibition of PDNS by Me-
tIMP, since ATP is necessary for the conversion of methionine into AdoMet by methionine 
adenosyltransferase (MAT). This second mechanism also accounts for the increase of met­
hionine observed as a result of 6MP treatment. Furthermore, Me-MPR also inhibits PDNS 
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via Me-tIMP, thereby inducing ATP depletion, so the same mechanism offers an explana-
tion for the effects of Me-MPR on AdoMet and methionine concentrations. These results 
indicate that ATP depletion is the predominant cause for the decrease of AdoMet and the 
AdoMet/AdoHcy ratio. 
The increase of AdoHcy, observed with both 6MP and Me-MPR can not be explained at 
this moment. It may be that Me-MPR directly or indirectly inhibits the conversion of 
AdoHcy into homocysteine by AdoHcy hydrolase, since Me-MPR is an analogue of 
adenosine, which is reported to exhibit feedback inhibition on this conversion. 
So, both 6MP and Me-MPR reduce the AdoMet/AdoHcy ratio, thereby influencing the met-
hylation capacity of the cells. The importance of the observed effects of 6MP and Me-MPR 
may be attributed to the fact that AdoMet is the methyl donor for many methyltransferases. 
The AdoMet/AdoHcy ratio is a major determinant of the methyltransferase activity, since 
AdoHcy is a potent inhibitor of several AdoMet-dependent transmethylases, and it is known 
that compounds which influence pool sizes, and especially the ratio of AdoMet/AdoHcy, 
may directly influence cellular methylation reactions, for instance methylation of DNA. 
Future developments 
The studies described in this thesis indicate that Me-tIMP formation attributes to cyto-
toxicity in Molt F4 cells, which exhibit a highly active purine de novo synthesis. This 
cytotoxicity may be attributed to inhibition of PDNS, and subsequent depletion of purine 
nucleotides, since prevention of this depletion results in prevention of cytotoxicity. 
However, the observed depletion of AdoMet, and the decrease of the AdoMet/AdoHcy may 
be an additional mechanism by which 6MP and Me-MPR exert their effects on cellular 
growth and cell viability. 
Changes in AdoMet/AdoHcy ratio may directly influence methylation reactions (53-62). 
Methylation of DNA is thought to play a major role in gene regulation (63). It is repor-ted 
that an increase of the AdoHcy concentration induces a decrease of DNA methylation 
(56,64). Furthermore, administration of AdoMet leads to chemoprevention of rat liver carci-
nogenesis, indicating a role of DNA methylation in tumorprogression (59). Drugs, which 
influence AdoMet/AdoHcy ratio can induce differentiation in several tumor cell lines 
(57,65). Antimetabolites, such as 5-fluorouracil, 5-fluorodeoxyuridine and methotrexate are 
associated with profound DNA hypermethylation in Molt-4 cells (58). With this respect it is 
notable that treatment of HTB-54 cells with 6-thioguanine was associated with hypomethyla-
tion of DNA (58). At the same time it has been reported that in differentiating Friend 
erythroleukemia cells, DNA is hypomethylated (66), and that inhibition of DNA methyl-
transferase leads to induction of differentiation in several cell lines (67,68). So, the role of 
DNA methylation in tumor development is far from elucidated. 
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Besides the effects on methylation of DNA by a decrease of the AdoMet/AdoHcy ratio 
many other methylation processes may be affected by 6MP and Me-MPR. AdoMet is a 
methyl donor for many methylation processes, such as methylation of proteins, RNA and 
phospholipids, as well as for small molecules (69), thereby regulating their functionality. 
So, drugs which influence the transmethylation pathway may also exert effects on the func-
tion of all these molecules. 
In conclusion, decrease of the AdoMet/AdoHcy ratio resulting from treatment with 6MP 
and Me-MPR may exert many effects in the cells, and may open a new field of research, 
possibly leading to a deeper understanding of the importance of methylation for 6MP 
cytotoxicity. 
References 
1. Elion, G.B., Burgi, E., and Hitchings, G.H. Studies on condensed pyrimidine systems IX. The 
synthesis of some 6-substituted purines. J. Am.Chem.Soc, 74:411-414, 1952. 
2. Bieber, S., Dietrich, L.S., Elion, G.B., Hitchings, G.H., and Martin, D.S. The incorporation of 
6-mercaptopurine-S35 into the nucleic acids of sensitive and non-sensitive transplantable mouse 
tumors. Cancer Res., 21: 228-231, 1961. 
3. LePage, G.A. Basic biochemical effects and mechanism of action of 6-thioguanine. Cancer Res., 
23: 1202-1206, 1963. 
4. Scannel, J.P. and Hitchings, G.H. Thioguanine in deoxyribonucleic acid from tumors of 
6-mercaptopurine-treated mice (31210). Proc.Soc.Exp.Biol.Med., 122: 627-629, 1966. 
5. Tidd, D.M. and Paterson, A.R.P. A biochemical mechanism for the delayed cytotoxic reaction 
of 6-mercaptopurine. Cancer Res., 34: 738-746, 1974. 
6. Maybaum, J. and Mandel, H.G. Differential chromatid damage induced by 6-thioguanine in 
CHO cells. Exp.Cell Res., 135: 465^*68, 1981. 
7. Maybaum, J. and Mandel, H.G. Unilateral chromatid damage: a new basis for 6-thioguanine 
cytotoxicity. Cancer Res., 43: 3852-3856, 1983. 
8. Christie, N.T., Drake, S., Meyn, R.E., and Nelson, J.A. 6-Thioguanine-induced DNA damage 
as a determinant of cytotoxicity in cultured chinese hamster ovary cells. Cancer Res., 44: 3665-
3671, 1984. 
9. Covey, J.M., D'Incaici, M., and Kohn, K.W. Production of DNA-protein crosslinks (DPC) by 
6-thioguanine (TG) and 2'-deoxy-6-thioguanosine (TGdR) in L1210 cells in vitro. 
Proc.Am.Assoc.Cancer Res., 27: 17, 1986. 
10. Bodell, W.J. Molecular dosimetry of sister chromatid exchange induction in 9L cells treated 
with 6-thioguanine. Mutagen., 6: 175-177, 1991. 
11. Pan, B.F. and Nelson, J.A. Characterization of the DNA damage in 6-thioguanine-treated cells. 
Biochem.Pharmacol., 40: 1063-1069, 1990. 
12. Lee, S.H. and Sartorelli, A.C. The effects of inhibitors of DNA biosynthesis on the cytotoxicity 
of 6-thioguanine. Cancer Biochem.Biophys., 5: 189-194, 1981. 
13. Tidd, D.M. and Paterson, A.R.P. Distinction between inhibition of purine nucleotide synthesis 
and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res., 34: 733-737, 1974. 
IIS 
Chapter 9 
14. Wotring, L.L. and Roti Roti, J.L. Thioguanine-induced S and G2 blocks and their significance 
to the mechanism of cytotoxicity. Cancer Res., 40: 1458-1462, 1980. 
15. Nelson, J.Α., Carpenter, J.W., Rose, L.M., and Adamson, D.J. Mechanisms of action of 
6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res., 35: 2872-2878, 1975. 
16. Bökkerink, J.P.M., De Abreu, R.A., Stet, E.H., and Damen, F.J.M. Cell-kinetics and 
biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphobla-
sts. KTm.Paediatr., 204: 293-298, 1992. 
17. Bökkerink, J.P.M., Stet, E.H., De Abreu, R.A., Damen, F.I.M., Hulscher, T.W., Bakker, 
M.A.H., and van Baal, J.M. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in 
human malignant T-lymphoblasts. Biochem.Pharmacol., 45: 1455-1463, 1993. 
18. Hill, D.L. and Bennett, L.L.Jr. Purification and properties of 5-phosphoribosyl pyrophosphate 
amidotransferase from adenocarcinoma 755 cells. Biochem., 8: 122-130, 1969. 
19. Henderson, J.F. and Khoo, M.K.Y. On the mechanism of feedback inhibition of purine 
biosynthesis de novo in Ehrlich ascites tumor cells in vitro. J.Biol.Chem., 240: 3104-3109, 1965. 
20. Caldwell, I.C., Henderson, J.F., and Paterson, A.R.P. The enzymic formation of 6-(methylmer-
capto)purine ribonucleoside 5'-phosphate. Can.J.Biochem., 44: 229-245, 1966. 
21. Broekman, R.W. and Chumley, S. Inhibition of formylglycinamide ribonucleotide synthesis in 
neoplastic cells by purines and analogs. Biochim.Biophys.Acta, 95: 365-379, 1964. 
22. Bennett, L.L.Jr. and Allan, P.W. Formation and significance of 6-methylthiopurine ribonucleo-
tide as a metabolite of 6-mercaptopurine. Cancer Res., 31: 152-158, 1971. 
23. Paterson, A.R.P. and Tidd, D.M. Antineoplastic and immunosuppressive agents part 2. In: 
Handbook of Pharmacology ХХХ Ш/2, pp. 384. 1975. 
24. McCollister, R.J., Gilbert, W.R., Ashton, D.M., and Wijngaarden, J.B. Pseudofeedback 
inhibition of purine synthesis by 6-mercaptopurine ribonucleotide and other purine analogues. 
J.Biol.Chem., 239: 1560-1563, 1964. 
25. Tay, В.S., Lilley, R.McC, Murray, A.W., and Atkinson, M.R. Inhibition of phosphoribosyl 
pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. 
Biochem.Pharmacol., 18: 936-938, 1969. 
26. Elion, G.B. Biochemistry and pharmacology of purine analogues. Fed.Proceed., 26: 898-904, 
1967. 
27. Wamick, T.C. and Paterson, A.R.P. Effect of methylthioinosine on nucleotide concentrations in 
L5178Y cells. Cancer Res., 33: 1711-1715, 1973. 
28. Woods, R.A., Henderson, R.M., and Henderson, J.F. Consequences of inhibition of purine 
biosynthesis de novo by 6-methylmercaptopurine ribonucleoside in cultured lymphoma L5178Y 
cells. Eur.J.Cancer, 14: 765-770, 1978. 
29. Scholar, E.M., Brown, P.R., and Parks, R.E.Jr. Synergistic effect of 6-mercaptopurine and 
6-methylmercaptopurine ribonucleoside on the levels of adenine nucleotides of sarcoma 180 cells. 
Cancer Res., 32: 259-269, 1972. 
30. Nelson, J.A. and Parks, R.E.Jr. Biochemical mechanisms for the synergism between 6-thiogua­
nine and 6-(methyImercapto)purine ribonucleoside in sarcoma 180 cells. Cancer Res., 32: 
2034-2041, 1972. 
31. Вбккегіпк, J.P.M., De Abreu, R.A., Bakker, M.A.H., Hulscher, T.W., van Baal, J.M., and de 
Vaan, G.A.M. Dose-related effects of methotrexate on purine and pyrimidine nucleotides and on 
cell-kinetic parameters in Molt-4 malignant human T-lymphoblasts. Biochem.Pharmacol., 35: 
3557-3564, 1986. 
116 
Chapter 9 
32. Schouten, T.J. 6-Mercaptopurine and 6-thioguanine: a fresh look on vintage anticancer drugs. 
Thesis 198S. 
33. Peters, G.J., Oosterhof, Α., and Veerkamp, J.H. Metabolism of phosphoribosylpyrophosphate 
in peripheral and phytohemagglutinin stimulated mammalian lymphocytes. Int.J.Biochem., 13: 
577-583, 1981. 
34. Cohen, M.B. and Sadee, W. Contributions of the depletions of guanine and adenine nucleotides 
to the toxicity of purine starvation in the mouse Τ lymphoma cell. Cancer Res., 43: 1587-1591, 
1983. 
35. Atkinson, D.E. Cellular energy metabolism and its regulation. New York: Academic Press, 
1977. 
36. Pall, M.L. GTP: a central regulator of cellular anabolism. Curr.Top.Cell.Regul., 25: 1-20, 
1985. 
37. Bourne, H.R., Sanders, D.A., and McCormick, F. The GTPase superfamily: a conserved switch 
for diverse cell functions. Nature, 348: 125-132, 1990. 
38. Cartier, M-F. Guanosine-'5-triphosphate hydrolysis and tubulin polymerization. Molec.Cell. 
Biochem., 47: 97-113, 1982. 
39. Lennard, L. and Lilleyman, J.S. Variable mercaptopurine metabolism and treatment outcome in 
childhood lymphoblastic leukemia. J.CIin.Oncol., 7: 1816-1823, 1989. 
40. Lennard, L., Keen, D., and Lilleyman, J.S. Oral 6-mercaptopurine in childhood leukemia: 
parent drug pharmacokinetics and active metabolite concentrations. Clin.Pharmacol.Ther., 40: 
287-292, 1986. 
41. Lennard, L., van Loon, J.Α., Lilleyman, J.S., and Weinshilboum, R.M. Thiopurine pharmaco­
kinetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thiogua­
nine nucleotide concentrations. Clin.Pharmacol.Ther., 41: 18-25, 1987. 
42. van Loon, J.A. and Weinshilboum, R.M. Human lymphocyte thiopurine methyltransferase 
pharmacokinetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimula­
tion. J.Pharmacol.Exp.Ther., 242: 21-26, 1987. 
43. Bennett, L.L.Jr., Broekman, R.W., Schnebli, HP., Chumley, S., Dixon, G.J., Schabel, 
F.M.Jr., Dulmadge, E.A., Skipper, H.E., Montgomery, J.Α., and Thomas, H.J. Activity and 
mechanism of action of 6-methylthiopurine ribonucleoside in cancer cells resistant to 6-mercaptopur­
ine. Nature, 205: 1276-1279, 1965. 
44. Shantz, G.D., Fontenelle, L.J., and Henderson, J.F. Inhibition of purine biosynthesis de novo 
and of Ehrlich ascites tumor cell growth by 6-methylmercaptopurine ribonucleoside. Biochem.Phar­
macol., 21: 1203-1206, 1972. 
45. Montgomery, J.A. and Struck, R.F. The relationship of the metabolism of anticancer agents to 
their activity. Prog.Drug res., 17: 320-409, 1973. 
46. Bennett, L.L.Jr., Schnebli, H.P., Vail, M.H., Allan, P.W., and Montgomery, J.A. Purine 
ribonucleoside kinase activity and resistance to some analogs of adenosine. Mol.Pharmacol., 2: 
432-M3, 1966. 
47. Caldwell, I.C., Henderson, J.F., and Paterson, A.R.P. Resistance to purine ribonucleoside 
analogues in an ascites tumor. Can.J.Biochem., 45: 735-744, 1967. 
48. Bökkerink, J.P.M. New aspects of methotrexate and 6-mercaptopurine. Thesis 1987. 
49. Schouten, T.J. 6-Mercaptopurine and 6-thioguanine: A fresh look on vintage anticancer drugs. 
Nijmegen: Stichting Studentenpers Nijmegen, 1985. 
117 
Chapter 9 
50. De Abreu, R.A., van Baal, J.M., and Bakkeren, J.A.J.M. High-performance liquid chromato­
graphic assay for identification and quantitation of nucleotides in lymphocytes and malignant 
lymphoblasts. J.Chromatogr., 227: 45-52, 1982. 
51. De Abreu, R.A., van Baal, J.M., Schouten, T.J., Schretlen, E.D.A.M., and De Bruijn, 
C.H.M.M. High-performance liquid chromatographic determination of plasma 6-mercaptopurine in 
clinically relevant concentrations. J.Chromatogr., 227: 526-533, 1982. 
52. van Baal, J.M., van Leeuwen, M.В., Schouten, T.J., and De Abreu, R.A. Sensitive high-per­
formance liquid chromatographic determination of 6-mercaptopurine, 6-thioguanine, 6-mercaptopu­
rine riboside and 6-thioguanosine in biological fluids. J.Chromatogr., 336: 422-428, 1984. 
53. Ueland, P.M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and 
S-adenosylhomocysteine hydrolase. Pharmacol.Rev., 34: 223-253, 1982. 
54. Hoffman, R.M. Altered methionine metabolism, DNA methylation and oncogene expression in 
carcinogenesis. Biochim.Biophys.Acta, 738: 49-87, 1984. 
55. Cox, R., Prescott, C, and Irving, С The effect of S-adenosylhomocysteine on DNA methyla­
tion in isolated rat liver nuclei. Biochim.Biophys.Acta, 474: 493-499, 1977. 
56. Gruenbaum, Y., Szyf, M., Cedar, H., and Razin, A. Methylation of replicating and post-replic­
ated mouse L-cell DNA. Proc.Natl.Acad.Sci.USA, 80: 4919-4921, 1983. 
57. Linevski, J., Cohen, M.B., Hartman, K.D., Knode, M.C., and Glazer, R.I. Effect of neplan-
ocin A on differentiation, nucleic acid methylation, and c-myc mRNA expression in human 
promyelocytic leukemia cells. Mol.Pharmacol., 28: 45-50, 1985. 
58. Nyce, J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer 
Res., 49: 5829-5836, 1989. 
59. Pascale, R.M., Marras, V., Simile, M.M., Daino, L., Pinna, G., Bennati, S., Carta, M., 
Seddaiu, Μ.Α., Massarelli, G., and Feo, F. Chemoprevention of rat liver carcinogenesis by 
S-adenosyl-L-methionine: A long-term study. Cancer Res., 52: 4979-4986, 1992. 
60. Chiang, P.K. and Cantoni, G.L. Perturbation of biochemical transmethylations by 3-deazaadeno-
sine in vivo. Biochem.Pharmacol., 28: 1897-1902, 1979. 
61. Bitonti, A.J., Baumann, R.J., Jarvi, E.T., McCarthy, JR., and McCann, P.P. Antimalarial 
activity of a 4'-5'-unsaturated 5'-fluoroadenosine mechanism-based inhibitor of S-adenosyl-L-homoc-
ysteine hydrolase. Biochem.Pharmacol., 40: 601-606, 1990. 
62. Greenberg, M.L., Chaffee, S., and Hershfield, M.S. Basis for resistance to 3-deazaaristeromy-
cin, an inhibitor of S-adenosylhomocysteine hydrolase, in human B-lymphoblasts. J.Biol.Chem., 
264: 795-803, 1989. 
63. Riggs, A.D. and Jones, P.A. 5-Methylcytosine, gene regulation, and cancer. Adv.Cancer Res., 
40: 1-30, 1983. 
64. Kredich, N.M. and Martin Jr, D.W. Role of S-adenosylhomocysteine in adenosine-mediated 
toxicity in cultured mouse T-lymphoma cells. Cell, 12: 931-938, 1977. 
65. Christman, J.K., Mendelsohn, N., Herzog, D., and Schneiderman, N. Effect of 5-azacytidine 
on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer 
Res., 43: 763-769, 1983. 
66. Christman, J.K., Weich, Ν., Schoenbrun, В., Schneiderman, Ν., and Acs, G. Hypomethylation 
of DNA during differentiation of Friend erythroleukemia cells. J.Cell Biol., 86: 366-370, 1980. 
67. Creusot, F., Acs, G., and Christman, J.K. Inhibition of DNA methyltransferase and induction 
of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. 
J.Biol.Chem., 257: 2041-2048, 1982. 
118 
Chapter 9 
68. Momparler, R.L., Bouchard, J., and Samson, J. Induction of differentiation and inhibition of 
DNA methylation in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine. Leuk.Res., £ 
1361-1366, 1985. 
69. Borchardt, R.T S-adenosyl-L-methionine-dependent macromolecule methyltransferases: potential 
targets for the design of chemotherapeutic agents. J.Medic.Chem., 23: 347-357, 1980. 
119 
Samenvatting 
6-mercaptopurine (6MP) is ongeveer 40 jaar geleden geïntroduceerd als geneesmiddel tegen 
leukemie. Tegenwoordig wordt het gebruikt voor de onderhoudsbehandeling van kinderen 
met acute lymfatische leukemie. 
6MP is een analoog van de purine base hypoxanthine. Dit wil zeggen dat 6MP qua structuur 
veel lijkt op hypoxanthine. Hypoxanthine heeft in cellen een aantal functies, het is onder 
andere een bouwsteen van DNA. 6MP vertoont zoveel overeenkomst met hypoxanthine dat 
het door cellen kan worden opgenomen en via dezelfde enzymen kan worden verwerkt als 
hypoxanthine. 
6MP kan via twee mechanismen de dood van tumorcellen bewerkstelligen. Voor beide 
mechanismen moet 6MP eerst worden omgezet in thio-IMP. Dit thio-IMP kan dan door 
twee metabole routes worden omgezet: 
Ten eerste kan thio-IMP via thio-GMP en thio-GDP worden omgezet in thio-GTP. Deze 
laatste verbinding kan worden ingebouwd in RNA en DNA van de tumorcellen. Inbouw van 
thio-GTP in DNA zorgt voor beschadiging van het DNA. Dit leidt tot celdood van de 
tumorcellen. Algemeen wordt aangenomen dat dit het belangrijkste mechanisme is waarop 
6MP celdood (cytotoxiciteit) veroorzaakt. 
Ten tweede kan thioIMP worden omgezet in methyl-thioIMP (Me-tIMP). Deze verbinding 
is een sterke remmer van de purine de novo synthese (PDNS), een metabole route waarbij 
in een aantal stappen nieuwe purine nucleotiden worden gevormd. Purine nucleotìden 
functioneren onder andere als bouwstenen voor RNA en DNA. Remming van de vorming 
van deze nucleotiden door Me-tIMP leidt tot een verminderde RNA en DNA-synthese. Aan-
gezien tumorcellen vanwege hun hoge groeisnelheid een snelle RNA en DNA-synthese 
hebben, zorgt remming hiervan voor verlaging van celgroei en dood van de tumorcellen. 
In dit proefschrift wordt het belang van de methylering ( = de aanmaak van Me-tIMP) voor 
de cytotoxiciteit van 6MP onderzocht. Hiervoor zijn experimenten gedaan met 6MP en met 
metylmercaptopurine ribonucleoside (Me-MPR). Deze laatste verbinding wordt ook omgezet 
in Me-tIMP. Dit is meteen de enige metaboliet is van Me-MPR. Daarom kan met Me-MPR 
heel specifiek onderzoek worden gedaan naar de effecten van vorming van Me-tIMP. In het 
onderzoek is gebruik gemaakt van Molt F4 cellen, een T-cel acute lymfatische cellijn. Dit is 
wezenlijk, aangezien leukemiecellen het uiteindelijke doel van de therapie vormen. 
Hoofdstuk 1 geeft een algemene inleiding over de kennis omtrent de cytotoxiciteit van 6MP 
en Me-MPR bij het begin van deze studie. 
In hoofdstuk 2 wordt de ontwikkeling van een gevoelige micro-assay voor het bepalen van 
de activiteit van IMP-dehydrogenase (IMPDH) beschreven. IMPDH is het snelheidsbepa-
lende enzym in de vorming van guanine nucleotiden. In Molt F4 blijkt het IMPDH twee 
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keer zo actief te zijn dan in een andere leukemische tumorcellijn, KM3. Dit duidt op een 
actief purine metabolisme in Molt F4 cellen. IMPDH activiteit kan worden geremd met 
behulp van mycofenolzuur (mycophenolic acid, MPA), een specifieke remmer van het 
enzym. 
In hoofdstuk 3 zijn de effecten van verschillende concentraties MPA op celgroei en celvitali-
teit van Molt F4 cellen beschreven. Cytotoxiciteit van MPA is concentratie-afhankelijk. 
Verder leidt incubatie van de cellen met MPA tot een tekort aan guanine nucleotiden, door­
dat IMPDH wordt geremd. Door toevoeging van guanosine, dat via de 'purine salvage 
route' kan worden omgezet in guanine nucleotiden, kunnen zowel het tekort aan guanine 
nucleotiden als de cytotoxiciteit worden opgeheven. 
In hoofdstuk 4 worden de effecten van de combinatie van MPA en 6MP op celgroei en cel-
vitaliteit beschreven. Vanwege de hoge cytotoxiciteit van MPA (hoofdstuk 3), is voor de 
combinatie-experimenten een lage concentratie MPA gebruikt. Combinatie van 0.5 μΜ 
MPA met 2 μΜ 6MP leidt tot een synergistische werking van de cytotoxiciteit. Verder 
worden met deze combinatie minder thioguanine nucleotiden en meer Me-tIMP gevormd in 
vergelijking met 6MP alleen. Dat zowel cytotoxiciteit als Me-tIMP concentratie toenemen 
leidt tot de conclusie dat Me-tIMP vorming van belang is voor 6MP cytotoxiciteit in 
leukemische cellen met een actieve PDNS. 
In hoofdstuk 5 is remming van de PDNS door Me-tIMP in meer detail onderzocht door ge­
bruik te maken van oplopende concentraties Me-MPR. Na incubatie van de cellen met 0,2 
μΜ Me-MPR blijkt er 500 pmol/106 cellen aan Me-tIMP te worden gevormd. Dit is vol­
doende om een maximale remming van de PDNS te veroorzaken, zoals blijkt uit het ontsta­
ne tekort aan purine nucleotiden en uit de toename van fosforibosylpyrofosfaat (PRPP). 500 
pmol/101 cellen Me-tIMP wordt ook na incubaties met 10 μΜ 6MP, en met 2 μΜ 6MP in 
combinatie met MPA gemeten. Vorming van Me-tIMP kan dus ook zeker een rol spelen bij 
de cytotoxiciteit van 6MP. 
De betekenis van remming van PDNS voor 6MP cytotoxiciteit is verder bestudeerd door 
middel van het voorkomen van het tekort aan purine nucleotiden. Dit kan op twee manie­
ren. Allereerst kan dit door toevoeging van amidoimidazole carboxamide ribonucleoside 
(AICAR), een metaboliet die in de route van de PDNS voorkomt, na de plaats waar Me-
tIMP deze route remt (hoofdstuk 6). Ten tweede kan het tekort aan purine nucleotiden 
worden voorkomen door gebruik te maken van metabolieten van de 'purine salvage route', 
zoals adenine, adenosine, inosine en guanosine (hoofdstuk 7). Door toevoeging van AICAR 
en van de laatstgenoemde metabolieten kan het tekort aan purine nucleotiden ten gevolge 
van de remming van de PDNS door Me-tIMP worden voorkomen. 
Toevoeging van AICAR aan incubatie met 6MP blijkt vooral het tekort aan adenine nucleo­
tiden te voorkomen (hoofdstuk 6). Tegelijkertijd neemt de cytotoxiciteit af. Aangezien 
AICAR echter ook zorgt voor een afname van de vorming van intracellulaire metabolieten 
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van 6MP (o.a. Me-tIMP), kan de verminderde cytotoxiciteit niet alleen worden toegeschre-
ven aan het voorkomen van het tekort aan purine nucleotides Verder wordt een deel van de 
cytotoxiciteit van 6MP veroorzaakt door inbouw van thioguanine nucleotiden in DNA. Dit 
maakt interpretatie van de resultaten van de combinatie 6MP/AICAR moeilijk. Om die re-
denen zijn deze experimenten ook gedaan met Me-MPR in plaats van 6MP. Toevoeging van 
AICAR aan incubatie met Me-MPR voorkomt het tekort aan purine nucleotiden, vooral ade-
nine nucleotiden. Dit leidt tot afname van de cytotoxiciteit. Dit wijst erop dat vooral het 
tekort aan adenine nucleotiden verantwoordelijk is voor de cytotoxiciteit van Me-tlMP. 
Combinatie van adenine, adenosine of inosine met Me-MPR leidt ook tot een herstel van de 
adenine nucleotide concentratie en daarmee van de vitaliteit van de cellen (hoofdstuk 7). 
Opnieuw wordt hierdoor het belang van adenine nucleotiden tekort voor cytotoxiciteit 
aangetoond. Indien guanosine wordt toegevoegd aan incubatie met een hoge concentratie 
Me-MPR wordt daarentegen de cytotoxiciteit versterkt. Dit komt omdat bij de vorming van 
guanine nucleotiden, adenine nucleotiden worden verbruikt en deze daardoor nagenoeg vol-
ledig uitgeput raken in de cellen. 
Vorming van Me-tIMP blijkt dus belangrijk te zijn voor cytotoxiciteit van 6MP. Voor vor-
ming van Me-tlMP is S-adenosylmethionine (AdoMet) nodig als methyldonor. Bij deze 
reactie wordt het AdoMet omgezet in S-adenosylhomocysteine (AdoHcy). In hoofdstuk 8 
worden de effecten van 6MP en Me-MPR op de AdoMet, AdoHcy en de methionine con-
centratie beschreven. 6MP blijkt een afname van AdoMet en een toename van AdoHcy en 
methionine te bewerkstelligen. De afname van AdoMet zou verklaard kunnen worden uit het 
verbruik van deze methyldonor voor de methylering van thio-IMP tot Me-tIMP. Echter ook 
Me-MPR zorgt voor een afname van AdoMet en een toename van AdoHcy en methionine, 
zodat verbruik van AdoMet voor de methylering van thio-IMP niet de enige oorzaak kan 
zijn voor de waargenomen effecten. AdoMet wordt gevormd uit methionine. Voor deze 
reactie is ATP p.odig. Zowel 6MP als Me-MPR worden omgezet in Me-tIMP, wat leidt tot 
remming van de PDNS en dus tot een tekort aan ATP. De afname van AdoMet en de 
toename van methionine als gevolg van 6MP en Me-MPR kunnen daarom waarschijnlijk 
worden verklaard door de remming van de PDNS. AdoMet is een methyl-donor voor veel 
methyleringsreacties, onder andere van eiwitten, fosfolipiden, RNA en DNA. DNA met-
hylering speelt een rol bij genexpressie. Methylering van eiwitten en fosfolipiden speelt een 
rol bij de functionaliteit van deze moleculen. Het is bekend dat geneesmiddelen die de 
concentratie AdoHcy verhogen, of de ratio tussen AdoMet en AdoHcy verlagen, de methy-
leringscapaciteit van cellen, en daarmee de methylering van bovengenoemde verbindingen 
kunnen veranderen, waardoor hun functionaliteit kan veranderen. Aangezien zowel 6MP als 
Me-MPR in staat blijken te zijn om AdoHcy te verhogen en de AdoMet/AdoHcy ratio te 
verlagen, is het mogelijk dat een deel van de cytotoxiciteit van deze cytostatica toegeschre-
ven kan worden aan beïnvloeding van de AdoMet en AdoHcy concentraties. 
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Stellingen 
behorende bij het proefschrift 
The relevance of methylation for thiopurine cytotoxicity 
In het openbaar te verdedigen 
op 20 januari 1994 
des namiddags te 1.30 uur precies 
door 
E.H. Stet 
I 
Uit de waarneming dat de cytotoxiciteit van 6-mercaptopurine in Molt F4 cellen toeneemt 
na remming van de synthese van thionucleotiden door mycophenolzuur, kan worden 
geconcludeerd dat methylering van 6-mercaptopurine in deze cellen een wezenlijke bijdrage 
levert aan de cytotoxiciteit van 6MP. 
dit proefschrift 
II 
Depletie van adenine nucleotiden als gevolg van remming van de purine de novo synthese 
lijkt belangrijker voor cytotoxiciteit van thiopurines dan depletie van guanine nucleotiden. 
dit proefschrift 
III 
De verlaging van de concentratie van S-adenosyl methionine die in Molt F4 cellen wordt 
veroorzaakt door zowel 6-mercaptopurine als methylmercaptopurine ribonucleoside kan 
leiden tot een verlaging van methylering van DNA en daarmee tot ontregeling van 
genexpressie en tot cytotoxiciteit. 
dit proefschrift 
IV 
Het synergisme tussen 6-mercaptopurine en methotrexaat wordt toegeschreven aan 
verhoging van de phosphoribosyl pyrophosphaat concentratie als gevolg van de 
methotrexaatbehandeling, waardoor meer 6-mercaptopurine kan worden ingebouwd in de 
cellen1. Een additionele verhoging van de cytotoxiciteit kan veroorzaakt worden, doordat 
methotrexaat, evenals 6-mercaptopurine, de S-adenosylmethionine concentratie verlaagt2,3. 
1. Bökkerink, J.P.M., Biochem.Pharmacol. 37 (1988) 2321-2327 
2. Scanion, K.J. Cancer Treatm. Rep. 67 (1983) 631-639 
3. Refsum H., TiPS 11 (1990), 411-416 
ν 
Het is bemoedigend dat na 40 jaar intensief onderzoek naar het werkingsmechanisme van 6-
mercaptopurine een mogelijk nieuw mechanisme voor deregulering van cellulaire processen 
in de vorm van effecten op de methyleringscapaciteit van maligne cellen kan worden 
gevonden. 
dit proefschrift 
VI 
De werking van 6-mercaptopurine op de verschillende metabole routes in de cel is dermate 
complex dat het buitengewoon moeilijk zal zijn om op grond van modelsystemen uitspraken 
te doen over de precieze mechanismen voor cytotoxiciteit van 6-mercaptopurine bij de 
behandeling van patiënten met acute lymfatische leukemie. 
VII 
Het is voor gemotiveerde en creatieve wetenschapsbeoefening onontbeerlijk om voldoende 
aandacht te besteden aan de beoefening van hobby's. 
VIII 
De billboard-slogan: "Roken, ook dat los je samen wel op" moet in analogie met 
rookreclames worden voorzien van de waarschuwing dat ook meeroken slecht is voor de 
gezondheid en hartklachten en kanker kan veroorzaken. 
Nijmegen, 20 januari 1994 Let Stet 

